<SEC-DOCUMENT>0001104659-24-070847.txt : 20240612
<SEC-HEADER>0001104659-24-070847.hdr.sgml : 20240612
<ACCEPTANCE-DATETIME>20240612161527
ACCESSION NUMBER:		0001104659-24-070847
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240612
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240612
DATE AS OF CHANGE:		20240612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Astrana Health, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		241038589

	BUSINESS ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801
		BUSINESS PHONE:		(626) 282-0288

	MAIL ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Apollo Medical Holdings, Inc.
		DATE OF NAME CHANGE:	20080715

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2416687d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:AMEH="http://apollomed.net/20240612">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_AMEH_apollomed.net_20240612 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20240612_20240612 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001083446 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000004" name="dei:EntityCentralIndexKey">0001083446</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ameh-20240612.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-06-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-12</xbrli:startDate>
        <xbrli:endDate>2024-06-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90D_edei--DocumentType_c20240612__20240612_zvNuXbyhINDe"><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)
of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities Exchange Act of 1934</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<b><span id="xdx_902_edei--DocumentPeriodEndDate_c20240612__20240612_z0ojHMB1ZDDi"><ix:nonNumeric contextRef="AsOf2024-06-12" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">June 12, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityRegistrantName_c20240612__20240612_zOFZ2slhVjSk"><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000011" name="dei:EntityRegistrantName">ASTRANA HEALTH, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its
Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 33%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20240612__20240612_zPAIG2BxqO3i"><ix:nonNumeric contextRef="AsOf2024-06-12" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityFileNumber_c20240612__20240612_zgcRDHUGUeii"><b><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000013" name="dei:EntityFileNumber">001-37392</ix:nonNumeric></b></span></span></td>
    <td style="width: 33%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20240612__20240612_zcuBPQQDwIq1"><b><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000014" name="dei:EntityTaxIdentificationNumber">95-4472349</ix:nonNumeric></b></span></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission </span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of Incorporation)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File Number)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_901_edei--EntityAddressAddressLine1_c20240612__20240612_zdrMNXrrs8Bi"><b><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000015" name="dei:EntityAddressAddressLine1">1668 S. Garfield Avenue</ix:nonNumeric></b></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20240612__20240612_zXvkxwEDFGO3"><b><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000016" name="dei:EntityAddressAddressLine2">2nd Floor</ix:nonNumeric></b></span>, <span id="xdx_904_edei--EntityAddressCityOrTown_c20240612__20240612_znvsUMSgxoed"><b><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000017" name="dei:EntityAddressCityOrTown">Alhambra</ix:nonNumeric></b></span>, <b><span id="xdx_909_edei--EntityAddressStateOrProvince_c20240612__20240612_zl3qFI20Ik0l"><ix:nonNumeric contextRef="AsOf2024-06-12" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20240612__20240612_zQQNQKnc1AR9"><b><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000019" name="dei:EntityAddressPostalZipCode">91801</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices) (Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_901_edei--CityAreaCode_c20240612__20240612_z1heozyXk1tg"><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000020" name="dei:CityAreaCode">626</ix:nonNumeric></span>) </b><span id="xdx_90D_edei--LocalPhoneNumber_c20240612__20240612_zKSOgqrGYxF8"><b><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000021" name="dei:LocalPhoneNumber">282-0288</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s Telephone Number, Including
Area Code</p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, if Changed Since
Last Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Wingdings"><span id="xdx_903_edei--WrittenCommunications_c20240612__20240612_zjgKGB4YVROj"><ix:nonNumeric contextRef="AsOf2024-06-12" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Wingdings"><span id="xdx_90C_edei--SolicitingMaterial_c20240612__20240612_zudPwmbdBMEc"><ix:nonNumeric contextRef="AsOf2024-06-12" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Wingdings"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20240612__20240612_zqpwqBaE5QDh"><ix:nonNumeric contextRef="AsOf2024-06-12" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20240612__20240612_zmkxXnxOWFd4"><ix:nonNumeric contextRef="AsOf2024-06-12" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 1pt; width: 35%; text-align: center; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Title of each class</span></td>
    <td style="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 1pt; width: 25%; text-align: center; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Trading Symbol(s)</span></td>
    <td style="border: Black 1pt solid; padding-top: 1pt; width: 40%; text-align: center; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 1pt; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--Security12bTitle_c20240612__20240612_zKW9f0LFLyX5"><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000026" name="dei:Security12bTitle">Common
    Stock</ix:nonNumeric></span></b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 1pt; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--TradingSymbol_c20240612__20240612_z0srHHumxQo2"><ix:nonNumeric contextRef="AsOf2024-06-12" id="Fact000027" name="dei:TradingSymbol">ASTH</ix:nonNumeric></span></b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 1pt; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--SecurityExchangeName_c20240612__20240612_zcgYduCUzeJd"><ix:nonNumeric contextRef="AsOf2024-06-12" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Emerging growth company&#160;</span><span style="font-family: Wingdings"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20240612__20240612_zT6vdqfcQc1j"><ix:nonNumeric contextRef="AsOf2024-06-12" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 5.02</b></td><td><b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.&#160;</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The stockholders of Astrana Health, Inc. (the
&#8220;Company&#8221;) approved the Astrana Health, Inc. 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;) at the 2024 Annual Meeting
of Stockholders of the Company (the &#8220;Annual Meeting&#8221;) held on June 12, 2024. The 2024 Plan was previously approved by the
Company&#8217;s Board of Directors (the &#8220;Board&#8221;). The 2024 Plan replaces the Company&#8217;s 2015 Equity Incentive Plan (the
&#8220;2015 Plan&#8221;). While no further awards will be made under the 2015 Plan, all awards granted under the 2015 Plan that were outstanding
on the date of stockholder approval of the 2024 Plan will remain outstanding in accordance with their terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Compensation Committee of the Board (the
&#8220;Compensation Committee&#8221;), which is comprised of non-employee directors, generally will administer awards granted under the
2024 Plan. To the extent permitted by applicable law, the Compensation Committee or the Board may delegate its authority to one or more
employees or directors of the Company. Further, the Board has reserved to itself the authority to grant awards to the non-employee members
of the Board, and the Board may reserve to itself any of the Compensation Committee&#8217;s other authority and may act as the administrator
of the 2024 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The 2024 Plan authorizes the grant of equity-based
and cash-based compensation awards to those officers and employees of, and consultants to, the Company and its subsidiaries who are selected
by the Compensation Committee, and the 2024 Plan also authorizes the Board to grant awards to the non-employee directors of the Company.
Awards under the 2024 Plan may be granted in the form of stock options, stock appreciation rights, restricted shares, restricted share
units and other share-based awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Subject to certain adjustments, the total
number of shares that may be delivered under the 2024 Plan will not exceed 2,100,000 shares, all of which may be issued pursuant to awards
of incentive stock options. Shares tendered or withheld to pay the exercise price of a stock option or to cover tax withholding will not
be added back to the number of shares available under the 2024 Plan. Upon exercise of any stock appreciation right that may be settled
in shares, the full number of shares subject to that award will be counted against the number of shares available under the 2024 Plan,
regardless of the number of shares used to settle the stock appreciation right upon exercise. To the extent that any award under the 2024
Plan or any award granted under the 2015 Plan is forfeited, or any option or stock appreciation right terminates, expires or lapses without
being exercised, the shares subject to such awards granted but not delivered will be added to the number of shares available for awards
under the 2024 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">No awards may be granted under the 2024 Plan
after February 27, 2034. The Board may, without stockholder approval, amend or terminate the 2024 Plan, except in any respect as to which
stockholder approval is required by the Plan, by law, regulation or the rules of an applicable stock exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">A summary of the 2024 Plan is included
in <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1083446/000110465924050983/tm2412398d4_def14a.htm#tP4OT">Proposal 4</a> of the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange
Commission on April 24, 2024 (the &#8220;Proxy Statement&#8221;), which summary is incorporated in its entirety herein by reference.
The summaries of the 2024 Plan contained herein and in the Proxy Statement do not purport to be complete and are subject to, and
qualified in their entirety by reference to, the full text of the 2024 Plan, a copy of which is filed as&#160;<a href="tm2416687d1_ex10-1.htm" style="-sec-extract: exhibit">Exhibit
10.1</a> to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 5.07</b></td><td><b>Submission of Matters to a Vote of Security Holders.&#160;</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company held its Annual Meeting on June
12, 2024. At the close of business on April 23, 2024, the record date for the Annual Meeting (the &#8220;Record Date&#8221;), there were
56,025,538 shares of common stock, par value $0.001 per share, of the Company issued and outstanding. At the Annual Meeting, there were
present in person or by proxy 42,337,157 shares of the Company&#8217;s common stock, representing stockholders entitled to cast approximately
75.6% of the total outstanding eligible votes and constituting a quorum. At the Annual Meeting:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">1.</td><td>Nine directors were elected to the Board, each to hold office until the 2025 Annual Meeting of Stockholders.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt">&#160;</div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">2.</td><td>The appointment of Ernst &amp; Young LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year
ending December 31, 2024 was ratified.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">3.</td><td>The compensation program for the Company&#8217;s named executive officers as disclosed in Proxy Statement was approved, on an advisory,
non-binding basis.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">4.</td><td>The 2024 Plan was approved.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">5.</td><td>An amendment to the Company&#8217;s Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer
exculpation was approved.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The voting results for each such matter were
as follows:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Proposal 1. Election of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominee</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Withheld</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth Sim, M.D.</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,510,162</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">647,957</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas S. Lam, M.D., M.P.H.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,619,083</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">539,036</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mitchell W. Kitayama</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,775,972</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">382,147</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David G. Schmidt</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,724,365</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,433,754</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linda Marsh</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,607,555</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">550,564</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Chiang</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,109,750</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,048,369</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Mazdyasni</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,086,620</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,071,499</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J. Lorraine Estradas, R.N., B.S.N. M.P.H.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,923,496</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,234,623</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weili Dai</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,051,962</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106,157</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Proposal 2. Ratification of Appointment
of Independent Registered Public Accounting Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Against</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Abstain</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">&#160;</td>
    <td style="width: 24%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,792,861</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">463,866</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80,430</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Proposal 3. Advisory Vote on Executive
Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Against</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Abstain</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">&#160;</td>
    <td style="width: 24%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,336,707</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">428,882</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">392,530</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Proposal 4. Approval of the 2024 Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Against</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Abstain</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">&#160;</td>
    <td style="width: 24%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,131,279</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">666,874</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">359,966</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Proposal 5. Approval of the Officer Exculpation
Amendment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Against</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Abstain</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">&#160;</td>
    <td style="width: 24%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,447,250</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">620,311</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,558</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,179,038</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt">&#160;</div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 9.01</b></td><td><b>Financial Statements and Exhibits.&#160;</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: White; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 10%; text-align: center"><b>Exhibit No.</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 88%; text-align: center"><b>Description of Exhibit</b></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-top: black 1pt solid; vertical-align: top; text-align: center"><a href="tm2416687d1_ex10-1.htm" style="-sec-extract: exhibit">10.1*</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-top: black 1pt solid; vertical-align: bottom"><a href="tm2416687d1_ex10-1.htm" style="-sec-extract: exhibit">Astrana Health, Inc. 2024 Equity Incentive Plan.</a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: center"><a href="tm2416687d1_ex10-2.htm" style="-sec-extract: exhibit">10.2*</a></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="tm2416687d1_ex10-2.htm" style="-sec-extract: exhibit">Form of Incentive Stock Option Agreement (2024 Equity Incentive Plan). </a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><a href="tm2416687d1_ex10-3.htm" style="-sec-extract: exhibit">10.3*</a></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="tm2416687d1_ex10-3.htm" style="-sec-extract: exhibit">Form of Nonqualified Stock Option Agreement (2024 Equity Incentive Plan). </a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: center"><a href="tm2416687d1_ex10-4.htm" style="-sec-extract: exhibit">10.4*</a></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="tm2416687d1_ex10-4.htm" style="-sec-extract: exhibit">Form of Restricted Stock Agreement (2024 Equity Incentive Plan). </a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><a href="tm2416687d1_ex10-5.htm" style="-sec-extract: exhibit">10.5*</a></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="tm2416687d1_ex10-5.htm" style="-sec-extract: exhibit">Form of Restricted Stock Unit Agreement (2024 Equity Incentive Plan). </a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: center">104</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Management contract or compensatory plan, contract or arrangement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="vertical-align: bottom"><b>ASTRANA HEALTH, INC.</b></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; width: 50%">Date: June 12, 2024</td>
    <td style="vertical-align: bottom; width: 5%">By: </td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 45%">/s/ Brandon K. Sim</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">Name:</td>
    <td style="vertical-align: bottom">Brandon K. Sim</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">Title:</td>
    <td style="vertical-align: bottom">Chief Executive Officer and President</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LppGBembFi1iFSkivga7SrDNlk38O5K3NLaIy8KyzHwzQsQip6WpkeE4LwvYY9PW2iOUeEZGe8LgyFbrFMIt8WKcZ2199/7AjAKDgZkMlNJB6Kx347BKQY6HcjRUY5BJmkxhthHRV8/Ink2F1htdg7YV7JhaNug1v/qEvX6SpebVVR2QnSGbQjKQvfwGJRMFW7rrB/HVQVFkIoq7iUTOdGuDa/H0aL8kLGpsQp3r6f9GH/u4Sno= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2416687d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 6pt; text-align: center; text-indent: -1.5pt"><B>ASTRANA HEALTH,
INC.<BR>
2024 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Establishment, Purpose, Duration</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Establishment</U>. Astrana Health, Inc. (the &ldquo;<U>Company</U>&rdquo;) hereby establishes an equity compensation plan to
be known as the Astrana Health, Inc. 2024 Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;), effective as of February 28, 2024 (the
 &ldquo;<U>Effective Date</U>&rdquo;), subject to the approval of the Plan by the stockholders of the Company at the 2024 Annual Meeting
of Stockholders. Definitions of certain capitalized terms used in the Plan are contained in Section 2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Purpose</U>. The purpose of the Plan is to attract and retain Directors, Consultants, officers and other key Employees of the
Company and its Subsidiaries, and to provide to such persons incentives and rewards for superior performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Duration</U>. No Award may be granted under the Plan on or after the tenth (10th) anniversary of the Effective Date, or such
earlier date as the Board shall determine. The Plan will remain in effect with respect to outstanding Awards until no Awards remain outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Termination of 2015 Plan</U>. If the Company&rsquo;s stockholders approve the Plan at the 2024 Annual Meeting of Stockholders,
the Company&rsquo;s 2015 Equity Incentive Plan (the &ldquo;<U>2015 Plan</U>&rdquo;) will terminate in its entirety effective upon stockholder
approval of the Plan, and no further awards may be granted under the 2015 Plan thereafter; provided that all outstanding awards under
the 2015 Plan as of the date of the 2024 Annual Meeting of Stockholders shall remain outstanding and shall be administered and settled
in accordance with their terms and the provisions of the 2015 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Definitions</B>. As used in the Plan, the following definitions shall apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Applicable Laws</U>&rdquo; means the applicable requirements relating to the administration of equity-based compensation
plans under U.S. state corporate laws, U.S. federal and state securities laws, the Code, the rules of any stock exchange or quotation
system on which the Shares are listed or quoted and the applicable laws of any other country or jurisdiction where Awards are granted
or administered or in which Participants work or reside.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Award</U>&rdquo; means an award of Nonqualified Stock Options, Incentive Stock Options, Stock Appreciation Rights, Restricted
Shares, Restricted Share Units or Other Share-Based Awards granted pursuant to the terms and conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Award Agreement</U>&rdquo; means either: (i) an agreement, in written or electronic format, entered into by the Company
and a Participant setting forth the terms and provisions applicable to an Award granted under the Plan; or (ii) a statement, in written
or electronic format, issued by the Company to a Participant describing the terms and provisions of such Award, which need not be signed
by the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Beneficial Owner</U>&rdquo; shall have the meaning ascribed to such term in Rule&nbsp;13d-3 under the Exchange Act and
any successor to such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Board</U>&rdquo; means the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>&ldquo;<U>Cause</U>&rdquo; as a reason for the Company&rsquo;s (or a Subsidiary&rsquo;s) termination of a Participant&rsquo;s Continuous
Service shall have the meaning specified in the applicable Award Agreement. In the absence of any definition in the Award Agreement, &ldquo;<U>Cause</U>&rdquo;
shall have the equivalent meaning or the same meaning as &ldquo;cause&rdquo; or &ldquo;for cause&rdquo; set forth in any employment, consulting,
or other agreement for the performance of services between the Participant and the Company or a Subsidiary or, in the absence of any such
agreement that defines the term, &ldquo;<U>Cause</U>&rdquo; shall mean: (i) conduct by the Participant constituting a material act of
willful misconduct in connection with the performance of the Participant&rsquo;s duties that results in loss, damage or injury that is
material to the Company or a Subsidiary; (ii) the commission by the Participant of any felony; (iii) continued, willful and deliberate
non-performance by the Participant of the Participant&rsquo;s duties to the Company or a Subsidiary (other than by reason of the Participant&rsquo;s
physical or mental illness, incapacity or disability); (iv) Participant&rsquo;s material breach of any employment agreement, consulting
agreement or agreement regarding nondisclosure of confidential information that results in loss, damage or injury that is material to
the Company or a Subsidiary; (v) willful failure to cooperate with a bona fide internal investigation or an investigation by regulatory
or law enforcement authorities, after being instructed by the Company or a Subsidiary to cooperate, or the willful destruction or failure
to preserve documents or other materials known to be relevant to such investigation or the willful inducement of others to fail to cooperate
or to produce documents or other materials in connection with such investigations; or (vi) fraud, embezzlement or theft against the Company
or any of its Subsidiaries or affiliates. With respect to the events in (i), (iii) and (iv) herein, the Company or a Subsidiary shall
have delivered written notice to the Participant of its intention to terminate the Participant&rsquo;s employment or other service for
Cause, which notice specifies in reasonable detail the circumstances claimed to give rise to the Company&rsquo;s (or Subsidiary&rsquo;s)
right to terminate the Participant&rsquo;s employment or other service for Cause and the Participant shall not have cured such circumstances
to the extent such circumstances are reasonably susceptible to cure, as determined by the Company (or Subsidiary) in good faith, within
thirty (30) days following the delivery of such notice to the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Change of Control</U>&rdquo; shall mean, unless otherwise specified in an Award Agreement, the occurrence of any of the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>Any Person becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing 50% or more of the total
voting power represented by the Company&rsquo;s then outstanding voting securities (excluding for this purpose any such voting securities
held by the Company or its Subsidiaries or by any employee benefit plan of the Company or a Subsidiary) pursuant to a transaction or a
series of related transactions; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>The closing of either (A) A merger or consolidation of the Company whether or not approved by the Board, other than a merger or
consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation)
more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such
corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B) the sale or disposition by the Company
of all or substantially all of the Company&rsquo;s assets; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;
</FONT>A change in the composition of the Board of Directors, as a result of which fewer than a majority of the directors are Incumbent
Directors. For this purpose, &ldquo;<U>Incumbent Directors</U>&rdquo; shall mean members of the Board who either (A)&nbsp;are directors
of the&nbsp;Company on the date twenty-four (24) months prior to the date of the event that may constitute a Change of Control, or (B)&nbsp;are
elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time
of such election or nomination (but shall not include an individual whose election or nomination is in connection with an actual or threatened
proxy contest relating to the election of directors to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Code</U>&rdquo; means the Internal Revenue Code of 1986, as amended, and any regulations promulgated and in effect thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>&ldquo;<U>Committee</U>&rdquo; means the Board&rsquo;s Compensation Committee or such other committee or subcommittee of the Board
as may be duly appointed to administer the Plan, and having such powers in each instance as shall be specified by the Board. To the extent
required by Applicable Laws, the Committee shall consist of two or more members of the Board, each of whom is a &ldquo;non-employee director&rdquo;
within the meaning of Rule 16b-3 promulgated under the Exchange Act and an &ldquo;independent director&rdquo; within the meaning of applicable
rules of any securities exchange upon which Shares are listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>&ldquo;<U>Company</U>&rdquo; means Astrana Health, Inc., a Delaware corporation (formerly known as Apollo Medical Holdings, Inc.),
and any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Consultant</U>&rdquo; means an independent contractor who (i) performs services for the Company or a Subsidiary in a
capacity other than as an Employee or Director, and (ii) qualifies as a consultant under the applicable rules of the SEC for registration
of shares on a Form S-8 Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>&ldquo;<U>Continuous Service</U>&rdquo; means the uninterrupted provision of services to the Company or any Subsidiary in any capacity
of Employee, Director or Consultant. Continuous Service shall not be considered to be interrupted in the case of (i) any approved leave
of absence; (ii) transfers among the Company, any Subsidiaries, or any successor entities, in any capacity of Employee, Director or Consultant;
or (iii) any change in status as long as the individual remains in the service of the Company, a Subsidiary, or successor of either in
any capacity of Employee, Director or Consultant (except as otherwise provided in such individual&rsquo;s Award Agreement). An approved
leave of absence shall include sick leave, military leave, or any other authorized personal leave.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Date of Grant</U>&rdquo; means the date specified by the Committee on which the grant of an Award is to be effective.
The Date of Grant shall not be earlier than the date of the resolution and action therein by the Committee to grant such Award. In no
event shall the Date of Grant be earlier than the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Director</U>&rdquo; means any individual who is a member of the Board and who is not an Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Effective Date</U>&rdquo; has the meaning given such term in Section&nbsp;1(a) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Employee</U>&rdquo; means any employee of the Company or a Subsidiary; provided, however, that for purposes of determining
whether any person may be a Participant for purposes of any grant of Incentive Stock Options, the term &ldquo;Employee&rdquo; has the
meaning given to such term in Section&nbsp;3401(c) of the Code, as interpreted by the regulations thereunder and Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Exchange Act</U>&rdquo; means the Securities Exchange Act of 1934 and the rules and regulations promulgated and in effect
thereunder, as such law, rules and regulations may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>&ldquo;<U>Fair Market Value</U>&rdquo; means the value of one Share on any relevant date, determined under the following rules:
(i) the closing sale price per Share on that date as reported on the Nasdaq Stock Market or such other principal exchange on which Shares
are then trading, if any, or if there are no sales on that date, on the next preceding trading day during which a sale occurred; (ii)
if the Shares are not reported on a principal exchange or national market system, the average of the closing bid and asked prices last
quoted on that date by an established quotation service for over-the-counter securities; or (iii) if neither (i) nor (ii) applies, (A)
with respect to Stock Options, Stock Appreciation Rights and any Award of stock rights that is subject to Section 409A of the Code, the
value as determined by the Committee through the reasonable application of a reasonable valuation method, taking into account all information
material to the value of the Company, within the meaning of Section 409A of the Code, and (B) with respect to all other Awards, the fair
market value as determined by the Committee in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Good Reason</U>&rdquo; shall, with respect to any Participant, have the meaning (if any) specified in the applicable
Award Agreement, or, in the absence of any definition in the Award Agreement, &ldquo;<U>Good Reason</U>&rdquo; shall have the equivalent
meaning or the same meaning (if any) as &ldquo;good reason&rdquo; or &ldquo;for good reason&rdquo; set forth in an applicable employment,
consulting or other agreement for the performance of services between the Participant and the Company or a Subsidiary, if any, that defines
such term. For purposes of clarity, a Participant shall have no rights under this Plan with respect to termination for &ldquo;Good Reason&rdquo;
unless and to the extent that such Participant is a party to an applicable Award Agreement, employment agreement, consulting agreement
or other agreement for the performance of services between the Participant and the Company or a Subsidiary that defines the term &ldquo;Good
Reason&rdquo; with respect to such Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>&ldquo;<U>Incentive Stock Option</U>&rdquo; or &ldquo;<U>ISO</U>&rdquo; means a Stock Option that is designated as an Incentive
Stock Option and that is intended to meet the requirements of Section&nbsp;422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Nonqualified Stock Option</U>&rdquo; means a Stock Option that is not intended to meet the requirements of Section&nbsp;422
of the Code or otherwise does not meet such requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Other Share-Based Award</U>&rdquo; means an equity-based or equity-related Award not otherwise described by the terms
of the Plan, granted in accordance with the terms and conditions set forth in Section&nbsp;10 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Participant</U>&rdquo; means any eligible individual as set forth in Section&nbsp;5 who holds one or more outstanding
Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Performance Award</U>&rdquo; has the meaning given such term in Section 14(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Performance Objectives</U>&rdquo; means the performance objective or objectives that may be established by the Committee
with respect to an Award granted pursuant to the Plan. Any Performance Objectives may relate to the performance of the Company or one
or more of its Subsidiaries, divisions, departments, units, functions, partnerships, joint ventures or minority investments, product lines
or products, or the performance of the individual Participant, and may include, without limitation, the Performance Objectives listed
in Section 14(a). The Performance Objectives may be made relative to the performance of a group of comparable companies, or a published
or special index that the Committee, in its sole discretion, deems appropriate, or the Company may select Performance Objectives as compared
to various stock market indices. Performance Objectives may be stated as a combination of such factors. Any Performance Objectives that
are financial metrics may be determined in accordance with United States Generally Accepted Accounting Principles (&ldquo;<U>GAAP</U>&rdquo;),
if applicable, or may be adjusted when established to include or exclude any items otherwise includable or excludable under GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Person</U>&rdquo; shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections
13(d) and 14(d) thereof, and shall include a &ldquo;group&rdquo; as defined in Section 13(d) thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;
</FONT>&ldquo;<U>Plan</U>&rdquo; means this Astrana Health, Inc. 2024 Equity Incentive Plan, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>&ldquo;<U>Qualified Termination</U>&rdquo; means any termination of a Participant&rsquo;s Continuous Service during the two-year
period commencing on the date of a Change of Control (i) by the Company, any of its Subsidiaries or the entity resulting from such Change
of Control other than for Cause (and not as a result of the Participant&rsquo;s disability or death), or (ii) if applicable, by the Participant
for Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;
</FONT>&ldquo;<U>Restricted Shares</U>&rdquo; means Shares granted or sold pursuant to Section&nbsp;8 hereof as to which neither the substantial
risk of forfeiture nor the prohibition on transfers referred to in such Section&nbsp;8 has expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>&ldquo;<U>Restricted Share Unit</U>&rdquo; means a grant or sale of the right to receive Shares or cash at the end of a specified
restricted period made pursuant to Section&nbsp;9 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ee)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;
</FONT>&ldquo;<U>SEC</U>&rdquo; means the United States Securities and Exchange Commission, or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ff)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Share</U>&rdquo; means a share of common stock of the Company, par value $0.001 per share, or any security into which
such Share may be changed by reason of any transaction or event of the type referred to in Section 16 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>&ldquo;<U>Stock Appreciation Right</U>&rdquo; means a right granted pursuant to Section&nbsp;7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>&ldquo;<U>Stock Option</U>&rdquo; means a right to purchase a Share granted to a Participant under the Plan in accordance with
the terms and conditions set forth in Section&nbsp;6 hereof. Stock Options may be either Incentive Stock Options or Nonqualified Stock
Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Subsidiary</U>&rdquo; means: (i) with respect to an Incentive Stock Option, a &ldquo;subsidiary corporation&rdquo; as
defined under Section 424(f) of the Code; and (ii) for all other purposes under the Plan, any corporation or other entity in which the
Company owns, directly or indirectly, a proprietary interest of more than fifty percent (50%) by reason of stock ownership or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Substitute Award</U>&rdquo; means an Award that is granted in assumption of, or in substitution or exchange for, an outstanding
award previously granted by an entity acquired directly or indirectly by the Company or with which the Company directly or indirectly
combines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT>&ldquo;<U>Ten Percent Stockholder</U>&rdquo; shall mean any Participant who owns more than 10% of the combined voting power of
all classes of stock of the Company, within the meaning of Section&nbsp;422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>2015 Plan</U>&rdquo; has the meaning given such term in Section&nbsp;1(d) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Shares Available Under the Plan.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Shares Available for Awards</U>. The maximum number of Shares that may be granted pursuant to Awards under the Plan shall be
two million one hundred thousand (2,100,000) Shares, all of which may be issued pursuant to Incentive Stock Options. Shares issued or
delivered pursuant to an Award may be authorized but unissued Shares, treasury Shares, including Shares purchased in the open market,
or a combination of the foregoing. The aggregate number of Shares available for issuance or delivery under the Plan shall be subject to
adjustment as provided in Section 16 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Share Counting</U>. Except as provided in Section 3(c) hereof, the following Shares shall not count against, or shall be added
back to, the Share limit in Section 3(a) hereof: (i) Shares covered by an Award that expires or is forfeited, canceled, surrendered, or
otherwise terminated; (ii) Shares covered by an award granted under the Prior Plan that, after stockholder approval of the Plan, is forfeited,
canceled, surrendered, or otherwise terminated; (iii) Shares covered by an Award that is settled only in cash; and (iv) Substitute Awards
(except as may be required by reason of the rules and regulations of any stock exchange or other trading market on which the Shares are
listed). This Section 3(b) shall apply to the number of Shares reserved and available for Incentive Stock Options only to the extent consistent
with applicable Code provisions relating to Incentive Stock Options under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Prohibition of Liberal Share Recycling</U>. Notwithstanding Section 3(b), the following Shares subject to an Award shall not
again be available for grant as described above, regardless of whether those Shares are actually issued or delivered to the Participant:
(i) Shares tendered in payment of the exercise price of a Stock Option; (ii) Shares withheld by the Company or any Subsidiary to satisfy
a tax withholding obligation with respect to an Award; and (iii) Shares that are repurchased by the Company with Stock Option proceeds.
Without limiting the foregoing, with respect to any Stock Appreciation Right that is settled in Shares, the full number of Shares subject
to the Award shall count against the number of Shares available for Awards under the Plan regardless of the number of Shares used to settle
the Stock Appreciation Right upon exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Limits on Awards to Certain Directors</U>. Notwithstanding any other provision of the Plan to the contrary and except as otherwise
provided in this Section 3(d), the aggregate grant date fair value (determined as of the Date of Grant in accordance with FASB ASC Topic
718) of all Awards granted to any Director (other than any Chair or Vice Chair of the Board) during any single fiscal year, together with
any cash compensation earned by such Director during such fiscal year, shall not exceed seven hundred fifty thousand dollars ($750,000).
For purposes of clarity, the limit set forth in this Section 3(d) shall not apply to the compensation of any Chair or Vice Chair of the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Administration of the Plan</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>In General</U>. The Plan shall be administered by the Committee. Except as otherwise provided by the Board, the Committee shall
have full and final authority in its discretion to take all actions determined by the Committee to be necessary in the administration
of the Plan, including, without limitation, discretion to: (i) select Award recipients; (ii)&nbsp;determine the sizes and types of Awards;
(iii) determine the terms and conditions of Awards in a manner consistent with the Plan; (iv) grant waivers of terms, conditions, restrictions
and limitations applicable to any Award, or (v) accelerate the vesting or exercisability of any Award, in a manner consistent with the
Plan; (vi) construe and interpret the Plan and any Award Agreement or other agreement or instrument entered into under the Plan; (vii)
establish, amend, or waive rules and regulations for the Plan&rsquo;s administration; and (viii) take such other action, not inconsistent
with the terms of the Plan, as the Committee deems appropriate. To the extent permitted by Applicable Laws, the Committee may, in its
discretion, delegate to one or more Directors or Employees any of the Committee&rsquo;s authority under the Plan. The acts of any such
delegates shall be treated hereunder as acts of the Committee with respect to any matters so delegated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Determinations</U>. The Committee shall have no obligation to treat Participants or eligible Employees, Directors and Consultants
uniformly, and the Committee may make determinations under the Plan selectively among Participants who receive, or Employees, Directors
or Consultants who are eligible to receive, Awards (whether or not such Participants or eligible Employees, Directors or Consultants are
similarly situated). All determinations and decisions made by the Committee pursuant to the provisions of the Plan and all related orders
and resolutions of the Committee shall be final, conclusive and binding on all persons, including the Company, its Subsidiaries, stockholders,
Directors, Consultants, Employees, Participants and their estates and beneficiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Authority of the Board</U>. The Board may reserve to itself any or all of the authority or responsibility of the Committee under
the Plan or may act as the administrator of the Plan for any and all purposes. To the extent the Board has reserved any such authority
or responsibility, or during any time that the Board is acting as administrator of the Plan, it shall have all the powers of the Committee
hereunder, and any reference herein to the Committee (other than in this Section 4(c)) shall include the Board. To the extent that any
action of the Board under the Plan conflicts with any action taken by the Committee, the action of the Board shall control. Without limiting
the foregoing, the Board specifically reserves the authority to approve and administer all Awards granted to Directors under the Plan,
and any references in the Plan to the &ldquo;Committee&rdquo; with respect to any such Awards shall be deemed to refer to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Eligibility and Participation</B>. Each Employee, Director and Consultant is eligible to participate in the Plan, upon selection
by the Committee, in the Committee&rsquo;s discretion. Subject to the provisions of the Plan, the Committee may, from time to time, select
from all eligible Employees, Directors and Consultants those to whom Awards shall be granted and shall determine, in its sole discretion,
the nature of any and all terms permissible by Applicable Laws and the amount of each Award. No Employee, Director or Consultant shall
have the right to be selected to receive an Award under the Plan, or, having been so selected, to be selected to receive future Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Stock Options</B>. Subject to the terms and conditions of the Plan, Stock Options may be granted to Participants in such number,
and upon such terms and conditions, as shall be determined by the Committee in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Award Agreement</U>. Each Stock Option shall be evidenced by an Award Agreement that shall specify the exercise price, the term
of the Stock Option, the number of Shares covered by the Stock Option, the conditions upon which the Stock Option shall become vested
and exercisable and such other terms and conditions as the Committee shall determine and which are not inconsistent with the terms and
conditions of the Plan. The Award Agreement also shall specify whether the Stock Option is intended to be an Incentive Stock Option or
a Nonqualified Stock Option. No dividend equivalents may be granted with respect to the Shares underlying a Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Exercise Price</U>. The exercise price per Share of a Stock Option shall be determined by the Committee at the time the Stock
Option is granted and shall be specified in the related Award Agreement; <U>provided</U>, <U>however</U>, that in no event shall the exercise
price per Share of any Stock Option (other than a Substitute Award) be less than one hundred percent (100%) of the Fair Market Value of
a Share on the Date of Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Term</U>. The term of a Stock Option shall be determined by the Committee and set forth in the related Award Agreement; <U>provided</U>,
<U>however</U>, that in no event shall the term of any Stock Option exceed ten (10) years from its Date of Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Exercisability</U>. Stock Options shall become vested and exercisable at such times and upon such terms and conditions as shall
be determined by the Committee and set forth in the related Award Agreement, subject to the terms and conditions of the Plan, including
the minimum vesting provisions of Section 12 hereof. Such terms and conditions may include, without limitation, the satisfaction of (i)
one or more Performance Objectives, and (ii) time-based vesting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Exercise of Stock Options</U>. Except as otherwise provided in the Plan or in a related Award Agreement, a Stock Option may
be exercised for all or any portion of the Shares for which it is then exercisable. A Stock Option shall be exercised by the delivery
of a notice of exercise to the Company or its designee in a form specified by the Company which sets forth the number of Shares with respect
to which the Stock Option is to be exercised and full payment of the exercise price for such Shares. The exercise price of a Stock Option
may be paid, in the discretion of the Committee and as set forth in the applicable Award Agreement: (i) in cash or its equivalent; (ii)
by tendering (either by actual delivery or attestation) previously acquired Shares having an aggregate Fair Market Value at the time of
exercise equal to the aggregate exercise price; (iii) by a cashless exercise (including by withholding Shares deliverable upon exercise
or through a broker-assisted arrangement to the extent permitted by Applicable Laws); (iv) by a combination of the methods described in
the foregoing clauses (i), (ii) and/or (iii); or (v) through any other method approved by the Committee in its sole discretion. As soon
as practicable after receipt of the notification of exercise and full payment of the exercise price, the Company shall cause the appropriate
number of Shares to be issued to the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;
</FONT><U>Special Rules Applicable to Incentive Stock Options</U>. Notwithstanding any other provision in the Plan to the contrary:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;Incentive
Stock Options may be granted only to Employees. The terms and conditions of Incentive Stock Options shall be subject to and comply with
the requirements of Section 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;To
the extent that the aggregate Fair Market Value of the Shares (determined as of the Date of Grant) with respect to which an Incentive
Stock Option is exercisable for the first time by any Participant during any calendar year (under all plans of the Company and its Subsidiaries)
is greater than $100,000 (or such other amount specified in Section 422 of the Code), as calculated under Section 422 of the Code, then
the Stock Option shall be treated as a Nonqualified Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;No
Incentive Stock Option shall be granted to any Participant who, on the Date of Grant, is a Ten Percent Stockholder, unless (A) the exercise
price per Share of such Incentive Stock Option is at least one hundred and ten percent (110%) of the Fair Market Value of a Share on the
Date of Grant, and (B) the term of such Incentive Stock Option shall not exceed five (5) years from the Date of Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Stock Appreciation Rights</B>. Subject to the terms and conditions of the Plan, Stock Appreciation Rights may be granted to Participants
in such number, and upon such terms and conditions, as shall be determined by the Committee in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Award Agreement</U>. Each Stock Appreciation Right shall be evidenced by an Award Agreement that shall specify the exercise
price, the term of the Stock Appreciation Right, the number of Shares covered by the Stock Appreciation Right, the conditions upon which
the Stock Appreciation Right shall become vested and exercisable and such other terms and conditions as the Committee shall determine
and which are not inconsistent with the terms and conditions of the Plan. No dividend equivalents may be granted with respect to the Shares
underlying a Stock Appreciation Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Exercise Price</U>. The exercise price per Share of a Stock Appreciation Right shall be determined by the Committee at the time
the Stock Appreciation Right is granted and shall be specified in the related Award Agreement; <U>provided</U>, <U>however</U>, that in
no event shall the exercise price per Share of any Stock Appreciation Right (other than a Substitute Award) be less than one hundred percent
(100%) of the Fair Market Value of a Share on the Date of Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Term</U>. The term of a Stock Appreciation Right shall be determined by the Committee and set forth in the related Award Agreement;
<U>provided</U>, <U>however</U>, that in no event shall the term of any Stock Appreciation Right exceed ten (10) years from its Date of
Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Exercisability of Stock Appreciation Rights</U>. A Stock Appreciation Right shall become vested and exercisable at such times
and upon such terms and conditions as may be determined by the Committee and set forth in the related Award Agreement, subject to the
terms and conditions of the Plan, including the minimum vesting provisions of Section 12 hereof. Such terms and conditions may include,
without limitation, the satisfaction of (i) one or more Performance Objectives, and (ii) time-based vesting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Exercise of Stock Appreciation Rights</U>. Except as otherwise provided in the Plan or in a related Award Agreement, a Stock
Appreciation Right may be exercised for all or any portion of the Shares for which it is then exercisable. A Stock Appreciation Right
shall be exercised by the delivery of a notice of exercise to the Company or its designee in a form specified by the Company which sets
forth the number of Shares with respect to which the Stock Appreciation Right is to be exercised. Upon exercise, a Stock Appreciation
Right shall entitle a Participant to an amount equal to (i) the excess of (A) the Fair Market Value of a Share on the exercise date over
(B) the exercise price per Share, multiplied by (ii) the number of Shares with respect to which the Stock Appreciation Right is exercised.
A Stock Appreciation Right may be settled in whole Shares, cash or a combination thereof, as specified by the Committee in the related
Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Restricted Shares.</B> Subject to the terms and conditions of the Plan, Restricted Shares may be granted or sold to Participants
in such number, and upon such terms and conditions, as shall be determined by the Committee in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Award Agreement</U>. Each Restricted Share Award shall be evidenced by an Award Agreement that shall specify the number of Restricted
Shares, the restricted period(s) applicable to the Restricted Shares, the conditions upon which the restrictions on the Restricted Shares
will lapse and such other terms and conditions as the Committee shall determine and which are not inconsistent with the terms and conditions
of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Terms, Conditions and Restrictions</U>. The Committee shall impose such other terms, conditions and/or restrictions on any Restricted
Shares as it may deem advisable, including, without limitation, a requirement that the Participant pay a purchase price for each Restricted
Share, restrictions based on the achievement of specific Performance Objectives, time-based restrictions or holding requirements or sale
restrictions placed on the Shares by the Company upon vesting of such Restricted Shares subject to the terms and conditions of the Plan,
including the minimum vesting provisions of Section 12 hereof. Unless otherwise provided in the related Award Agreement or required by
Applicable Law, the restrictions imposed on Restricted Shares shall lapse upon the expiration or termination of the applicable restricted
period and the satisfaction of any other applicable terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Custody of Certificates</U>. To the extent deemed appropriate by the Committee, the Company may retain any certificates representing
Restricted Shares in the Company&rsquo;s possession until such time as all terms, conditions and/or restrictions applicable to such Shares
have been satisfied or lapse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Rights Associated with Restricted Shares during Restricted Period</U>. During any restricted period applicable to Restricted
Shares: (i) the Restricted Shares may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated; (ii) unless
otherwise provided in the related Award Agreement, the Participant shall be entitled to exercise any voting rights associated with such
Restricted Shares; and (iii) the Participant shall be entitled to any dividends and other distributions paid with respect to such Restricted
Shares during the restricted period; <U>provided, however</U>, that any dividends with respect to unvested Restricted Shares shall be
accumulated or deemed reinvested in additional Restricted Shares (as determined by the Committee in its sole discretion and set forth
in the applicable Award Agreement), subject to the same terms and conditions as the original Award (including service-based vesting conditions
and any Performance Objectives) until such Award is earned and vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Restricted Share Units.</B> Subject to the terms and conditions of the Plan, Restricted Share Units may be granted or sold to Participants
in such number, and upon such terms and conditions, as shall be determined by the Committee in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Award Agreement</U>. Each Restricted Share Unit Award shall be evidenced by an Award Agreement that shall specify the number
of units, the restricted period(s) applicable to the Restricted Share Units, the conditions upon which the restrictions on the Restricted
Share Units will lapse, the time and method of payment of the Restricted Share Units to the Participant, and such other terms and conditions
as the Committee shall determine and which are not inconsistent with the terms and conditions of the Plan, including the minimum vesting
provisions of Section 12 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Terms, Conditions and Restrictions</U>. The Committee shall impose such other terms, conditions and/or restrictions on any Restricted
Share Units as it may deem advisable, including, without limitation, a requirement that the Participant pay a purchase price for each
Restricted Share Unit, restrictions based on the achievement of specific Performance Objectives or time-based restrictions or holding
requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Form of Settlement</U>. Restricted Share Units may be settled in whole Shares, cash or a combination thereof, as specified by
the Committee in the related Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Other Share-Based Awards</B>. Subject to the terms and conditions of the Plan, Other Share-Based Awards may be granted to Participants
in such number, and upon such terms and conditions, as shall be determined by the Committee in its sole discretion, subject to the terms
and conditions of the Plan, including the minimum vesting provisions of Section 12 hereof. Other Share-Based Awards are Awards that are
valued in whole or in part by reference to, or otherwise based on the Fair Market Value of, Shares, and shall be in such form as the Committee
shall determine, including without limitation, unrestricted Shares (subject to the limitations of Section&nbsp;12 hereof) or time-based
or performance-based units that are settled in Shares and/or cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Award Agreement</U>. Each Other Share-Based Award shall be evidenced by an Award Agreement that shall specify the terms and
conditions upon which the Other Share-Based Award shall become vested, if applicable, the time and method of settlement, the form of settlement
and such other terms and conditions as the Committee shall determine and which are not inconsistent with the terms and conditions of the
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Form of Settlement</U>. An Other Share-Based Award may be settled in whole Shares, cash or a combination thereof, as specified
by the Committee in the related Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Dividend Equivalents</B>. Awards granted under the Plan (other than Stock Options and Stock Appreciation Rights) may provide the
Participant with dividend equivalents, payable on a contingent basis and either in cash or in additional Shares, as determined by the
Committee in its sole discretion and set forth in the related Award Agreement; <U>provided</U>, <U>however</U>, that any dividend equivalents
with respect to an unvested Award shall be either accumulated in cash or deemed reinvested in additional Restricted Share Units, subject
to the same terms and conditions as the original Award (including service-based vesting conditions and the achievement of any Performance
Objectives) until such Award is earned and vested. Notwithstanding anything to the contrary herein, no dividend equivalents may be granted
under the Plan with respect to the Shares underlying any Stock Option or Stock Appreciation Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Minimum Vesting Provisions</B>. Notwithstanding any other provision of the Plan to the contrary, Awards granted under the Plan
shall not become vested or exercisable in full any earlier than the first anniversary of the Date of Grant of the Award (excluding, for
this purpose, any (a) Substitute Awards, and (b) Awards to Directors that vest in full no later than the earlier of the first anniversary
of the date of grant or the next annual meeting of stockholders (provided that such vesting period is not less than 50 weeks after the
Date of Grant)); <U>provided</U>, <U>however</U>, that the Committee may grant Awards without regard to the foregoing minimum vesting
requirement with respect to a maximum of five percent (5%) of the available share reserve authorized for issuance under the Plan pursuant
to Section 3(a) hereof; and, <U>provided further</U> that the foregoing restriction does not apply to the Committee&rsquo;s discretion
to provide for accelerated exercisability or vesting of any Award, including in cases of retirement, death, disability, other termination
of employment or a Change of Control, by the terms of the Award Agreement or otherwise. For purposes of clarity, an Award that vests or
becomes exercisable in installments over a period that ends on or after the first anniversary of the Date of Grant of the Award shall
be considered to comply with the minimum vesting provisions of this Section 12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Compliance with Section 409A</B>. Awards granted under the Plan shall be designed and administered in such a manner that they are
either exempt from the application of, or comply with, the requirements of Section 409A of the Code. To the extent that the Committee
determines that any award granted under the Plan is subject to Section 409A of the Code, the Award Agreement shall incorporate the terms
and conditions necessary to avoid the imposition of an additional tax under Section 409A of the Code upon a Participant. Notwithstanding
any other provision of the Plan or any Award Agreement (unless the Award Agreement provides otherwise with specific reference to this
Section 13): (a) an Award shall not be granted, deferred, accelerated, extended, paid out, settled, substituted, modified or adjusted
under the Plan in a manner that would result in the imposition of an additional tax under Section 409A of the Code upon a Participant;
and (b) if an Award is subject to Section 409A of the Code, and if the Participant holding the award is a &ldquo;specified employee&rdquo;
(as defined in Section 409A of the Code, with such classification to be determined in accordance with the methodology established by the
Company), then, to the extent required to avoid the imposition of an additional tax under Section 409A of the Code upon a Participant,
no distribution or payment of any amount shall be made before the date that is six (6) months following the date of such Participant&rsquo;s
 &ldquo;separation from service&rdquo; (as defined in Section 409A of the Code) or, if earlier, the date of the Participant&rsquo;s death.
Although the Company intends to administer the Plan so that Awards will be exempt from, or will comply with, the requirements of Section
409A of the Code, the Company does not warrant that any Award under the Plan will qualify for favorable tax treatment under Section 409A
of the Code, or any other provision of federal, state, local, or non-United States law. The Company shall not be liable to any Participant
for any tax, interest, or penalties the Participant might owe as a result of the grant, holding, vesting, exercise, or payment of any
Award under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Performance Objectives</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>In General</U>. As provided in the Plan, the vesting, exercisability and/or payment of any Award may be conditioned upon the
achievement of one or more Performance Objectives (any such Award, a &ldquo;<U>Performance Award</U>&rdquo;). Any Performance Objectives
shall be based on the achievement of one or more criteria selected by the Committee, in its discretion, which may include, but shall not
be limited to, the following: (i) revenue; (ii) earnings before interest, taxes, depreciation and amortization, as adjusted (EBITDA as
adjusted); (iii) income before income taxes and minority interests; (iv) operating income; (v) pre- or after-tax income; (vi) average
accounts receivable; (vii) cash flow; (viii) cash flow per share; (ix) net earnings; (x) basic or diluted earnings per share; (xi) return
on equity; (xii) return on assets; (xiii) return on capital; (xiv) growth in assets; (xv) economic value added; (xvi) share price performance;
(xvii) total stockholder return; (xviii) improvement or attainment of expense levels; (xix) market share or market penetration; (xx) business
expansion, and/or acquisitions or divestitures; or (xxi) environmental, social or governance metrics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Establishment of Performance Objectives</U>. With respect to any Performance Award, the Committee shall establish in writing
the Performance Objectives, the performance period, and any formula for computing the payout of the Performance Awards. Such terms and
conditions shall be established in writing during the first ninety days of the applicable performance period (or by such other date as
may be determined by the Committee, in its discretion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Certification of Performance</U>. Prior to payment, exercise or vesting of any Performance Award, the Committee will certify
in writing whether the applicable Performance Objectives and other material terms imposed on such Performance Award have been satisfied,
and, if they have, ascertain the amount of the payout or vesting of the Performance Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Adjustments</U>. If the Committee determines that a change in the Company&rsquo;s business, operations, corporate structure
or capital structure, or in the manner in which it conducts its business, or other events or circumstances render the Performance Objectives
unsuitable, the Committee may, in its discretion and without the consent of any Participant, adjust such Performance Objectives or the
related level of achievement, in whole or in part, as the Committee deems appropriate and equitable, including, without limitation, to
exclude the effects of events that are unusual in nature or infrequent in occurrence (as determined in accordance with applicable financial
accounting standards), cumulative effects of tax or accounting changes, discontinued operations, acquisitions, divestitures and material
restructuring or asset impairment charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Transferability</B>. Except as otherwise determined by the Committee, no Award or dividend equivalents paid with respect to any
Award shall be transferable by the Participant except by will or the laws of descent and distribution; provided, that if so determined
by the Committee, each Participant may, in a manner established by the Board or the Committee, designate a beneficiary to exercise the
rights of the Participant with respect to any Award upon the death of the Participant and to receive Shares or other property issued or
delivered under such Award. Except as otherwise determined by the Committee, Stock Options and Stock Appreciation Rights will be exercisable
during a Participant&rsquo;s lifetime only by the Participant or, in the event of the Participant&rsquo;s legal incapacity to do so, by
the Participant&rsquo;s guardian or legal representative acting on behalf of the Participant in a fiduciary capacity under state law and/or
court supervision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Adjustments</B>. In the event of any equity restructuring (within the meaning of Financial Accounting Standards Board Accounting
Standards Codification Topic 718, or any successor thereto), such as a stock dividend, stock split, reverse stock split, spinoff, rights
offering, or recapitalization through a large, nonrecurring cash dividend, the Committee shall cause there to be an equitable adjustment
in the number and kind of Shares specified in Section&nbsp;3 of the Plan and, with respect to outstanding Awards, in the number and kind
of Shares subject to outstanding Awards and the exercise price or other price of Shares subject to outstanding Awards, in each case to
prevent dilution or enlargement of the rights of Participants. In the event of any other change in corporate capitalization, or in the
event of a merger, consolidation, liquidation, or similar transaction, the Committee may, in its sole discretion, cause there to be an
equitable adjustment as described in the foregoing sentence, to prevent dilution or enlargement of rights; <U>provided</U>, <U>however</U>,
that, unless otherwise determined by the Committee, the number of Shares subject to any Award shall always be rounded down to a whole
number. Moreover, in the event of any such transaction or event, the Committee, in its discretion, may provide in substitution for any
or all outstanding Awards such alternative consideration (including cash) as it, in good faith, may determine to be equitable in the circumstances,
and may require in connection therewith the surrender of all Awards so replaced. Notwithstanding the foregoing, the Committee shall not
make any adjustment pursuant to this Section 16 that would (a) cause any Stock Option intended to qualify as an ISO to fail to so qualify,
(b) cause an Award that is otherwise exempt from Section 409A of the Code to become subject to Section 409A, or (c)&nbsp;cause an Award
that is subject to Section 409A of the Code to fail to satisfy the requirements of Section 409A . The determination of the Committee as
to the foregoing adjustments, if any, shall be conclusive and binding on all Participants and any other persons claiming under or through
any Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Fractional Shares</B>. The Company shall not be required to issue or deliver any fractional Shares pursuant to the Plan and, unless
otherwise provided by the Committee, fractional shares shall be settled in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Withholding Taxes</B>. To the extent required by Applicable Laws, a Participant shall be required to satisfy, in a manner satisfactory
to the Company or Subsidiary, as applicable, any withholding tax obligations that arise by reason of the exercise of a Stock Option or
Stock Appreciation Right, the vesting of or settlement of Shares under an Award, an election pursuant to Section&nbsp;83(b) of the Code
or otherwise with respect to an Award. The Company and its Subsidiaries shall not be required to issue or deliver Shares, make any payment,
or recognize the transfer or disposition of any Shares, until such withholding tax obligations are satisfied. The Committee may permit
or require these obligations to be satisfied by having the Company withhold a portion of the Shares that otherwise would be issued or
delivered to a Participant upon exercise of a Stock Option or Stock Appreciation Right or upon the vesting or settlement of an Award,
or by tendering Shares previously acquired, in each case having a value (as determined by the Company) equal to the amount required to
be withheld. Any such elections are subject to such conditions or procedures as may be established by the Committee and may be subject
to disapproval by the Committee. In no event will the value of the Shares to be withheld or tendered pursuant to this Section 18 to satisfy
applicable withholding taxes exceed the amount of taxes required to be withheld based on the maximum statutory tax rates in the applicable
taxing jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Non-U.S. Participants</B>. Without amending the Plan, the Committee may grant Awards to Participants who are foreign nationals,
or who are subject to Applicable Laws of one or more non-United States jurisdictions, on such terms and conditions different from those
specified in the Plan as may in the judgment of the Committee be necessary or desirable to foster and promote achievement of the purposes
of the Plan, and, in furtherance of such purposes, the Committee may approve such sub-plans, supplements to or amendments, modifications,
restatements or alternative versions of this Plan as may be necessary or advisable to comply with provisions of Applicable Laws of other
countries in which the Company or its Subsidiaries operate or have Employees or Consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Compensation Recovery Policy</B>. Any Award granted to a Participant shall be subject to forfeiture or repayment pursuant to the
terms of the Company&rsquo;s Compensation Recovery Policy as in effect from time to time (and any similar, supplemental, or successor
policy).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Change of Control</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;<U>In
General</U>. The provisions of this Section 21 shall apply, notwithstanding any other provision of this Plan to the contrary, except to
the extent otherwise specifically provided in a Participant&rsquo;s Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;<U>Awards
that are Assumed</U>. To the extent outstanding Awards granted under this Plan are assumed, converted or replaced by the resulting entity
in the event of a Change of Control (or, if the Company is the resulting entity in the Change of Control, to the extent such Awards are
continued by the Company), then, except as otherwise provided in the applicable Award Agreement or in another written agreement with the
Participant, or in a Company severance plan applicable to the Participant: (i) any outstanding Awards that are subject to Performance
Objectives shall be converted to service-vesting awards by the resulting entity, as if &ldquo;target&rdquo; performance had been achieved
as of the date of the Change of Control, and shall continue to vest based on the Participant&rsquo;s Continuous Service during the remaining
performance period or other period of required service, and (ii) all other Awards shall continue to vest during the applicable vesting
period, if any. Notwithstanding the preceding sentence, if a Participant incurs a Qualified Termination, then upon such termination, all
outstanding Awards shall become fully vested and any such Awards that are Stock Options or Stock Appreciation Rights shall become fully
exercisable and shall remain exercisable for the full duration of their term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;<U>Awards
that are not Assumed</U>. To the extent outstanding Awards granted under this Plan are not assumed, converted or replaced by the resulting
entity in connection with a Change of Control (or, if the Company is the resulting entity in the Change of Control, to the extent such
Awards are not continued by the Company), then effective immediately prior to the Change of Control, except as otherwise provided in the
applicable Award Agreement or in another written agreement with the Participant, or in a Company severance plan applicable to the Participant:
(i) all outstanding Awards held by the Participant that may be exercised shall become fully exercisable and shall remain exercisable for
the full duration of their term, (ii) all restrictions with respect to outstanding Awards shall lapse, with any specified Performance
Objectives with respect to outstanding Awards deemed to be satisfied at the &ldquo;target&rdquo; level, and (iii) all outstanding Awards
shall become fully vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;<U>Cancellation
Right</U>. The Committee may, in its sole discretion and without the consent of Participants, either by the terms of the Award Agreement
applicable to any Award or by resolution adopted prior to the occurrence of the Change of Control, provide that any outstanding Award
(or a portion thereof) shall, upon the occurrence of such Change of Control, be cancelled in exchange for a payment in cash or other property
(including shares of the resulting entity in connection with a Change of Control) in an amount equal to the excess, if any, of the Fair
Market Value of the Shares subject to the Award, over any exercise price related to the Award, which amount may be zero if the Fair Market
Value of a Share on the date of the Change of Control does not exceed the exercise price per Share of the applicable Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>22.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Amendment, Modification and Termination</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>In General</U>. The Board may at any time and from time to time, alter, amend, suspend or terminate the Plan in whole or in
part; <U>provided</U>, <U>however</U>, that no alteration or amendment that requires stockholder approval in order for the Plan to comply
with any rule promulgated by the SEC or any securities exchange on which Shares are listed or any other Applicable Laws shall be effective
unless such amendment is approved by the requisite vote of stockholders of the Company entitled to vote thereon within the time period
required under such applicable listing standard, rule or law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Adjustments to Outstanding Awards</U>. The Committee may, in its sole discretion and without the consent of any Participant,
at any time (i) provide that all or a portion of a Participant&rsquo;s Stock Options, Stock Appreciation Rights and other Awards in the
nature of rights that may be exercised shall become fully or partially exercisable; (ii) provide that all or a part of the time-based
vesting restrictions on all or a portion of the outstanding Awards shall lapse, and/or that any Performance Objectives or other performance-based
criteria with respect to any Awards shall be deemed to be wholly or partially satisfied; or (iii) waive any other limitation or requirement
under any such Award, in each case, as of such date as the Committee may, in its sole discretion, declare.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Prohibition on Repricing Without Stockholder Approval</U>. Except for adjustments made pursuant to Sections 16 or 21 hereof,
the Committee will not, without the approval of the stockholders of the Company, authorize the amendment of any outstanding Stock Option
or Stock Appreciation Right to reduce the exercise price of such Award. No Stock Option or Stock Appreciation Right will be cancelled
and replaced with an Award having a lower exercise price, or for another Award, or for cash, without approval of the stockholders of the
Company, except as provided in Sections 16 or 21 hereof. Furthermore, no Stock Option or Stock Appreciation Right will provide for the
payment, at the time of exercise, of a cash bonus or grant or sale of another Award without further approval of the stockholders of the
Company. This Section 22(c) is intended to prohibit the repricing of &ldquo;underwater&rdquo; Stock Options or Stock Appreciation Rights
without stockholder approval and will not be construed to prohibit the adjustments provided for in Sections 16 or 21 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Effect on Outstanding Awards</U>. Notwithstanding any other provision of the Plan to the contrary (other than Sections 14(d),
16, 21, 22(b) and 24(e) hereof, which specifically do not require the consent of Participants), no termination, amendment, suspension,
or modification of the Plan or an Award Agreement shall adversely affect in any material way any Award previously granted under the Plan,
without the written consent of the Participant holding such Award; <U>provided</U>, <U>however</U>, that the Committee may modify an ISO
held by a Participant to disqualify such Stock Option from treatment as an &ldquo;incentive stock option&rdquo; under Section 422 of the
Code without the Participant&rsquo;s consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>23.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Applicable Laws</B>. The obligations of the Company with respect to Awards under the Plan shall be subject to all Applicable Laws
and such approvals by any governmental agencies as the Committee determines may be required. The Plan and each Award Agreement shall be
governed by the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction
or interpretation of the Plan to the substantive law of another jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>24.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Miscellaneous</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Stock Ownership Guidelines</U>. By accepting any Award under the Plan, each Participant shall thereby agree to comply with the
terms and conditions of any stock ownership guidelines the Company may maintain or establish, as the same may be applicable to the Participant
from time to time, including any applicable stock retention requirements thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Deferral of Awards</U>. Except with respect to Stock Options, Stock Appreciation Rights and Restricted Shares, the Committee,
in its discretion, may permit Participants to elect to defer the issuance or delivery of Shares or the settlement of Awards in cash under
the Plan pursuant to such rules, procedures or programs as it may establish for purposes of the Plan. The Committee also may provide that
deferred issuances and settlements include the payment or crediting of dividend equivalents or interest on the deferral amounts. Any elections
and deferrals permitted under this provision shall comply with Section&nbsp;409A of the Code, including setting forth the time and manner
of the election (including a compliant time and form of payment), the date on which the election is irrevocable, and whether the election
can be changed until the date it is irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Right of Continued Service</U>. The Plan shall not confer upon any Participant any right with respect to continuance of employment
or other service with the Company or any Subsidiary, nor shall it interfere in any way with any right the Company or any Subsidiary would
otherwise have to terminate such Participant&rsquo;s employment or other service at any time. Awards granted under the Plan shall not
be considered a part of any Participant&rsquo;s normal or expected compensation or salary for any purposes, including, but not limited
to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards,
pension or retirement or welfare benefits or similar payments, and in no event shall any Award be considered as compensation for, or relating
in any way to, past services for the Company or any Subsidiary or affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Unfunded, Unsecured Plan</U>. Neither a Participant nor any other person shall, by reason of participation in the Plan, acquire
any right or title to any assets, funds or property of the Company or any Subsidiary, including without limitation, any specific funds,
assets or other property which the Company or any Subsidiary may set aside in anticipation of any liability under the Plan. A Participant
shall have only a contractual right to an Award or the amounts, if any, payable under the Plan, unsecured by any assets of the Company
or any Subsidiary, and nothing contained in the Plan shall constitute a guarantee that the assets of the Company or any Subsidiary shall
be sufficient to pay any benefits to any person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Severability</U>. If any provision of the Plan or an Award Agreement is or becomes invalid, illegal or unenforceable in any
jurisdiction, or would disqualify the Plan or any Award under any Applicable Law, as determined by the Committee, such provision shall
be construed or deemed amended or limited in scope to conform to such Applicable Law or, in the discretion of the Committee, it shall
be stricken and the remainder of the Plan shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;<U>Acceptance
of Plan</U>. By accepting any benefit under the Plan, each Participant and each person claiming under or through any such Participant
shall be conclusively deemed to have indicated their acceptance and ratification of, and consent to, all of the terms and conditions of
the Plan, any Award Agreement and any action taken under the Plan by the Committee, the Board or the Company, in any case in accordance
with the terms and conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;<U>Successors</U>.
All obligations of the Company under the Plan and with respect to Awards granted hereunder shall be binding on any successor to the Company,
whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or other event, or a sale
or disposition of all or substantially all of the business and/or assets of the Company and references to the &ldquo;Company&rdquo; herein
and in any Award Agreements shall be deemed to refer to such successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[END OF DOCUMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>tm2416687d1_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASTRANA HEALTH, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>INCENTIVE STOCK OPTION GRANT NOTICE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Astrana Health, Inc. (the
 &ldquo;<U>Company</U>&rdquo;), pursuant to its 2024 Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;), hereby grants to the individual
listed below (&ldquo;<U>Participant</U>&rdquo;) an option (the &ldquo;<U>Option</U>&rdquo;) to purchase the number of shares of the Company&rsquo;s
common stock, par value $0.001 (&ldquo;<U>Shares</U>&rdquo;), set forth below for the exercise price per Share set forth below (the &ldquo;<U>Exercise
Price</U>&rdquo;). The Option subject to all of the terms and conditions set forth herein and in the Stock Option Agreement attached hereto
as <U>Exhibit A</U> (the &ldquo;<U>Option Agreement</U>&rdquo;) and the Plan, each of which are incorporated herein by reference. Capitalized
terms used but not defined in this Incentive Stock Option Grant Notice (the &ldquo;<U>Grant Notice</U>&rdquo;) and the Option Agreement
shall have the meanings given to such terms in the Plan. The Option is intended to qualify as an &ldquo;incentive stock option&rdquo;
within the meaning of Section 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify">Participant:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 60%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Grant Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Total Number of Option Shares:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Exercise Price:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Vesting Schedule:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Expiration Date:</TD>
    <TD STYLE="text-align: justify">the tenth anniversary of the Grant Date</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: -3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B><I>Important
Notice: This Agreement shall be void, AND THE OPTION SHALL BE FORFEITED AUTOMATICALLY, if THE AGREEMENT has not been SIGNED by Participant
and returned to the Company within 30 days after the Grant Date.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By signing below, Participant
agrees to be bound by the terms and conditions of the Plan, the Option Agreement and this Grant Notice. Participant has reviewed the Option
Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing
this Grant Notice and fully understands all provisions of this Grant Notice, the Option Agreement and the Plan. Participant hereby agrees
to accept as binding, conclusive and final all decisions or interpretations of the Company and the Committee (as defined in the Plan)
upon any questions arising under the Plan, this Grant Notice or the Option Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the undersigned have executed this Grant Notice effective as of the Grant Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASTRANA HEALTH, INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO INCENTIVE STOCK OPTION GRANT NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>STOCK OPTION AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.&#8239;&#8239;&#8239;&#8239;General.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&#8239;&#8239;&#8239;&#8239;<U>Defined
Terms</U>. Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Grant Notice, unless
the context clearly indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2 &#8239;&#8239;&#8239;&#8239;<U>Incorporation
of Terms of Plan</U>. The Option subject to the terms and conditions of the Plan which are incorporated herein by reference. In the event
of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.&#8239;&#8239;&#8239;&#8239;Grant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1 &#8239;&#8239;&#8239;&#8239;<U>Grant
of Option</U>. In consideration of Participant&rsquo;s employment with the Company or a Subsidiary and for other good and valuable consideration,
effective as of the Grant Date set forth in the Grant Notice (the &ldquo;<U>Grant Date</U>&rdquo;), the Company grants to Participant
the Option, upon the terms and conditions set forth in the Plan and this Agreement, subject to adjustments as provided in Article VIII
of the Plan. The Option is intended to qualify as an &ldquo;incentive stock option&rdquo; within the meaning of Section 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2 &#8239;&#8239;&#8239;&#8239;<U>Consideration
to the Company</U>. In consideration of the grant of the Option by the Company, Participant agrees to render faithful and efficient services
to the Company or a Subsidiary. Nothing in the Plan or this Agreement shall confer upon Participant any right to continue in the employ
or service of the Company or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and its Subsidiaries,
which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever,
with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and
Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&#8239;&#8239;&#8239;&#8239;<U>Exercise
Price</U>. The exercise price of the Option shall be the amount per Share set forth in the Grant Notice, subject to adjustment as provided
in Article VIII of the Plan (the &ldquo;<U>Exercise Price</U>&rdquo;). Payment of the Exercise Price shall be made in accordance with
Section 3.2 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&#8239;&#8239;&#8239;&#8239;<U>Term
of Option</U>. The Option shall terminate on the Expiration Date as specified in the Grant Notice, but shall be subject to earlier termination
as provided herein or in the Plan. Upon termination of Participant&rsquo;s employment or service for any reason, any vested portion of
the Option shall remain exercisable for 90 days thereafter, and any unvested portion of the Option shall be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.&#8239;&#8239;&#8239;&#8239;Vesting,
Exercise, Restrictions, Etc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1 &#8239;&#8239;&#8239;&#8239;<U>Vesting</U>.
Subject to the terms and conditions of the Plan, the Option shall vest and become exercisable at such times as are set forth in the Grant
Notice; provided, however, no portion of the Option that has not become vested at the date of Participant&rsquo;s termination of employment
or service for any reason, with or without cause (including, but not limited to, death, Disability or Retirement), shall thereafter become
vested, except as may be otherwise provided by the Committee or as set forth in a written agreement between the Company and Participant.
Notwithstanding any provision of this Agreement to the contrary, in the event of a Change of Control, the treatment of the Option will
be governed by any applicable provisions of Section 21 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&#8239;&#8239;&#8239;&#8239;<U>Method
of Exercise</U>. Subject to the terms and conditions of this Agreement, the Option, to the extent vested and exercisable, may be exercised,
in whole or in part, by written notice to the Company or its designee, in substantially the form of&nbsp;attached hereto (or in such other
form acceptable to the Company, which may include electronic notice). Such notice shall state the number of Shares with respect to which
the Option is being exercised and shall be signed by the person exercising the Option (which signature may be provided electronically
in a form acceptable to the Company). Payment of the Exercise Price for such Shares shall be made in cash or its equivalent, or in such
other manner as may be approved by the Committee pursuant to the Plan. The Company shall deliver such Shares as soon as practicable after
the notice shall be received, provided, however, that (a) no fractional Shares shall be issued pursuant to this Option, and (b) the Company
may delay issuance of such Shares until completion of any action or obtaining of any consent, which the Company deems necessary under
any Applicable Laws (including, without limitation, state securities or &ldquo;blue sky&rdquo; laws). The Shares as to which the Option
shall have been so exercised shall be registered in the Company&rsquo;s share register in the name of the person so exercising the Option
and shall be delivered as provided above to or upon the written order of the person exercising the Option. In the event the Option shall
be exercised, by any person other than Participant, such notice shall be accompanied by appropriate proof of the right of such person
to exercise the Option. All Shares that shall be purchased upon the exercise of the Option as provided herein shall be fully paid and
nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&#8239;&#8239;&#8239;&#8239;<U>Restrictions</U>.
The Option shall not be transferable by Participant otherwise than by will or by the laws of descent and distribution, provided that the
Company may permit Participant to designate a beneficiary to exercise any vested portion of the Option in the event of Participant&rsquo;s
death. Except as provided above in this paragraph, the Option shall be exercisable, during Participant&rsquo;s lifetime, only by Participant
and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution,
attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of the Option or of any
rights granted hereunder contrary to the provisions of this Section&nbsp;3.3, or the levy of any attachment or similar process upon the
Option shall be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4 &#8239;&#8239;&#8239;&#8239;<U>Tax
Withholding</U>. Participant acknowledges and agrees that any income or other taxes due from Participant with respect to the Option (upon
exercise of the Option, the sale of Shares issued pursuant to the Option or otherwise) shall be Participant&rsquo;s responsibility. Without
limiting the foregoing, the parties agree that to the extent the Company or any Subsidiary is required to withhold any federal, state,
local, foreign or other taxes in connection with the exercise of the Option, then the Company or Subsidiary (as applicable) shall retain
a number of Shares otherwise deliverable hereunder with a value equal to the required withholding (based on the fair market value of the
Shares on the applicable date); provided that in no event shall the value of the Shares retained exceed the minimum amount of taxes required
to be withheld or such other amount that will not result in a negative accounting impact. Notwithstanding the foregoing, (a) to the extent
permitted by the Committee, Participant may elect, in accordance with procedures adopted by the Company from time to time, to&nbsp;pay
or provide for payment of the required tax withholding, and (b) in the event that the Company or any Subsidiary is required to withhold
taxes at any time other than upon exercise of the Option, the Company may withhold applicable taxes from other compensation payable to
Participant or require Participant to make arrangements satisfactory to the Company to provide for such tax withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5 &#8239;&#8239;&#8239;&#8239;<U>Rights
as Stockholder</U>. Participant shall have no rights as a stockholder with respect to Shares subject to this Agreement until exercise
of the Option and registration of the Shares in the Company&rsquo;s share register in the name of Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6&#8239;&#8239;&#8239;&#8239;<U>Compensation
Recovery Policy</U>. The Option and any Shares that may be delivered pursuant to this Agreement are subject to forfeiture or repayment
as may be provided pursuant to the Company&rsquo;s Compensation Recovery Policy (or any successor compensation recovery policy), as in
effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.7&#8239;&#8239;&#8239;&#8239;<U>Disqualifying
Disposition</U>. Participant agrees that, should Participant make a &ldquo;<U>disposition</U>&rdquo; (as defined in Section 424(c) of
the Code) of all or any of the Shares acquired pursuant to the Option within two years from the date of the grant of the Option or within
one year after the delivery of such Shares upon exercise of the Option, Participant shall immediately advise the Company in writing as
to the occurrence of the disposition and the price realized upon the disposition of such Shares. Participant agrees that Participant shall
maintain all Shares acquired pursuant to the Option in Participant&rsquo;s name so long as Participant maintains beneficial ownership
of such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.&#8239;&#8239;&#8239;&#8239;Other
Provisions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1 &#8239;&#8239;&#8239;&#8239;<U>Administration</U>.
The Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation
and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules. All actions taken and all interpretations
and determinations made by the Committee in good faith shall be final, binding and conclusive upon Participant, the Company and all other
interested persons. No member of the Committee or the Board, or any employee or officer of the Company, shall be personally liable for
any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2 &#8239;&#8239;&#8239;&#8239;<U>Adjustments
Upon Specified Events</U>. The Committee may accelerate the vesting and exercisability of the Option in such circumstances as it, in its
sole discretion, may determine. In addition, upon the occurrence of certain events relating to the Company&rsquo;s common stock contemplated
by the Plan (including, without limitation, an extraordinary cash dividend on such Shares), the Committee shall make such adjustments
as the Committee deems appropriate to the Option in order to preserve the benefits intended to be made available to Participant under
this Agreement. Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided
in this Agreement and the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3 &#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of
the Company (or any other person or entity as designated by the Committee) at the Company&rsquo;s principal office, and any notice to
be given to Participant shall be addressed to Participant at Participant&rsquo;s last address reflected on the Company&rsquo;s records.
By a notice given pursuant to this Section 4.3, either party may hereafter designate a different address for notices to be given to that
party. A notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited
(with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4 &#8239;&#8239;&#8239;&#8239;<U>Titles
and Headings</U>. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5 &#8239;&#8239;&#8239;&#8239;<U>Governing
Law</U>. The laws of the State of Delaware, without reference to any conflict of law principles thereof, shall govern the interpretation,
validity, administration, enforcement and performance of the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6 &#8239;&#8239;&#8239;&#8239;<U>Conformity
to Laws</U>. Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions
of the Securities Act of 1933, as amended, the Exchange Act and the Code, and any and all regulations and rules promulgated thereunder,
state securities laws and regulations and all other applicable law. Notwithstanding anything herein to the contrary, the Plan shall be
administered, and the Option is granted and shall be administered only in such a manner as to conform to such laws, rules and regulations.
To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such
laws, rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7 &#8239;&#8239;&#8239;&#8239;<U>Amendments,
Suspension and Termination</U>. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified,
suspended or terminated at any time or from time to time by the Committee or the Board; <U>provided</U>, <U>however</U>, that except as
may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect
the Option in any material way without the prior written consent of Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8 &#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall
inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in Section
3.3 hereof, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9 &#8239;&#8239;&#8239;&#8239;<U>Not
a Contract of Employment</U>. Nothing in this Agreement or in the Plan shall confer upon Participant any right to continue to serve as
an employee or other service provider of the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10 &#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement</U>. The Plan, the Grant Notice and this Agreement (including all Exhibits thereto) constitute the entire agreement of the parties
and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11&#8239;&#8239;&#8239;&#8239;<U>Relation
to Other Benefits</U>. Any economic or other benefit to Participant under this Agreement or the Plan shall not be taken into account in
determining any benefits to which Participant may be entitled under any profit-sharing, retirement or other benefit or compensation plan
maintained by the Company or any of its Subsidiaries or affiliates, except as expressly provided in writing in such other plan&rsquo;s
governing instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12&#8239;&#8239;&#8239;&#8239;<U>Data
Privacy</U>. In order to administer the Plan, the Company may process personal data about Participant. Such data includes, but is not
limited to, the information provided in this Agreement and any changes thereto, other appropriate personal and financial data about Participant
such as home address and business addresses and other contact information, and any other information that might be deemed appropriate
by the Company to facilitate the administration of the Plan. Participant hereby gives explicit consent to the Company to process any such
personal data. Participant also gives explicit consent to the Company to transfer any such personal data outside the country in which
Participant works or is employed, including, if Participant is not a U.S. resident, to the United States, to transferees that shall include
the Company and other persons who are designated by the Company to administer the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13&#8239;&#8239;&#8239;&#8239;<U>Electronic
Delivery</U>. Participant hereby consents and agrees to electronic delivery of any documents that the Company may elect to deliver, including,
but not limited to, the Plan document, Plan Summary and Prospectus, grant or award notifications, account statements, annual and quarterly
reports, and all other forms of communications (&ldquo;<U>Prospectus Information</U>&rdquo;) in connection with this and any other Award
made or offered under the Plan. Participant has the right at any time to request that the Company deliver written copies of any and all
Prospectus Information at no charge. Participant also hereby consents to any and all procedures the Company has established or may establish
for an electronic signature system for delivery and acceptance of any such Prospectus Information that the Company may elect to deliver
and agrees that Participant&rsquo;s electronic response or signature is the same as, and shall have the same force and effect as, Participant&rsquo;s
manual signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><U>NOTICE OF EXERCISE
OF STOCK OPTION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt">To:</TD>
    <TD STYLE="font-size: 10pt"><B>Astrana Health, Inc.</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">I hereby exercise my
Stock Option to purchase _________ shares (the &ldquo;<U>Shares</U>&rdquo;) of the common stock, $0.001 par value, of Astrana Health,
Inc. (the &ldquo;<U>Company</U>&rdquo;), at the Exercise Price of $____&nbsp;per Share, pursuant to and subject to the terms of that Incentive
Stock Option Grant Notice dated ______________, 20__ and the Astrana Health, Inc. 2024 Equity Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">I understand the nature
of the investment I am making and the financial risks thereof. I am aware that it is my responsibility to have consulted with competent
tax and legal advisors about the relevant national, state and local income tax and securities laws affecting the exercise of the Option
and the purchase and subsequent sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">I am paying the Exercise
Price for the Shares as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 53%; padding-bottom: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt">Participant (signature)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt">Print Name</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt">Date</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B></B></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>tm2416687d1_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASTRANA HEALTH, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>NONQUALIFIED STOCK OPTION GRANT NOTICE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Astrana Health, Inc. (the
 &ldquo;<U>Company</U>&rdquo;), pursuant to its 2024 Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;), hereby grants to the individual
listed below (&ldquo;<U>Participant</U>&rdquo;) an option (the &ldquo;<U>Option</U>&rdquo;) to purchase the number of shares of the Company&rsquo;s
common stock, par value $0.001 (&ldquo;<U>Shares</U>&rdquo;), set forth below for the exercise price per Share set forth below (the &ldquo;<U>Exercise
Price</U>&rdquo;). The Option subject to all of the terms and conditions set forth herein and in the Stock Option Agreement attached hereto
as <U>Exhibit A</U> (the &ldquo;<U>Option Agreement</U>&rdquo;) and the Plan, each of which are incorporated herein by reference. Capitalized
terms used but not defined in this Nonqualified Stock Option Grant Notice (the &ldquo;<U>Grant Notice</U>&rdquo;) and the Option Agreement
shall have the meanings given to such terms in the Plan. The Option is a nonqualified stock option, and shall not be treated as an &ldquo;incentive
stock option&rdquo; (within the meaning of Section 422 of the Code).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify">Participant:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 60%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Grant Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Total Number of Option Shares:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Exercise Price:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Vesting Schedule:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Expiration Date:</TD>
    <TD STYLE="text-align: justify">the tenth anniversary of the Grant Date</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: -3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B><I>Important
Notice: This Agreement shall be void, AND THE OPTION SHALL BE FORFEITED AUTOMATICALLY, if THE AGREEMENT has not been SIGNED by Participant
and returned to the Company within 30 days after the Grant Date.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By signing below, Participant
agrees to be bound by the terms and conditions of the Plan, the Option Agreement and this Grant Notice. Participant has reviewed the Option
Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing
this Grant Notice and fully understands all provisions of this Grant Notice, the Option Agreement and the Plan. Participant hereby agrees
to accept as binding, conclusive and final all decisions or interpretations of the Company and the Committee (as defined in the Plan)
upon any questions arising under the Plan, this Grant Notice or the Option Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the undersigned have executed this Grant Notice effective as of the Grant Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASTRANA HEALTH, INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO NONQUALIFIED STOCK OPTION GRANT NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>STOCK OPTION AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.&#8239;&#8239;&#8239;&#8239;General.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&#8239;&#8239;&#8239;&#8239;<U>Defined
Terms</U>. Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Grant Notice, unless
the context clearly indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2 &#8239;&#8239;&#8239;&#8239;<U>Incorporation
of Terms of Plan</U>. The Option subject to the terms and conditions of the Plan which are incorporated herein by reference. In the event
of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.&#8239;&#8239;&#8239;&#8239;Grant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1 &#8239;&#8239;&#8239;&#8239;<U>Grant
of Option</U>. In consideration of Participant&rsquo;s employment with the Company or a Subsidiary and for other good and valuable consideration,
effective as of the Grant Date set forth in the Grant Notice (the &ldquo;<U>Grant Date</U>&rdquo;), the Company grants to Participant
the Option, upon the terms and conditions set forth in the Plan and this Agreement, subject to adjustments as provided in Article VIII
of the Plan. The Option is a nonqualified stock option, and shall not be treated as an &ldquo;incentive stock option&rdquo; (within the
meaning of Section 422 of the Code).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2 &#8239;&#8239;&#8239;&#8239;<U>Consideration
to the Company</U>. In consideration of the grant of the Option by the Company, Participant agrees to render faithful and efficient services
to the Company or a Subsidiary. Nothing in the Plan or this Agreement shall confer upon Participant any right to continue in the employ
or service of the Company or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and its Subsidiaries,
which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever,
with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and
Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&#8239;&#8239;&#8239;&#8239;<U>Exercise
Price</U>. The exercise price of the Option shall be the amount per Share set forth in the Grant Notice, subject to adjustment as provided
in Article VIII of the Plan (the &ldquo;<U>Exercise Price</U>&rdquo;). Payment of the Exercise Price shall be made in accordance with
Section 3.2 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&#8239;&#8239;&#8239;&#8239;<U>Term
of Option</U>. The Option shall terminate on the Expiration Date as specified in the Grant Notice, but shall be subject to earlier termination
as provided herein or in the Plan. Upon termination of Participant&rsquo;s employment or service for any reason, any vested portion of
the Option shall remain exercisable for 90 days thereafter, and any unvested portion of the Option shall be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.&#8239;&#8239;&#8239;&#8239;Vesting,
Exercise, Restrictions, Etc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1 &#8239;&#8239;&#8239;&#8239;<U>Vesting</U>.
Subject to the terms and conditions of the Plan, the Option shall vest and become exercisable at such times as are set forth in the Grant
Notice; provided, however, no portion of the Option that has not become vested at the date of Participant&rsquo;s termination of employment
or service for any reason, with or without cause (including, but not limited to, death, Disability or Retirement), shall thereafter become
vested, except as may be otherwise provided by the Committee or as set forth in a written agreement between the Company and Participant.
Notwithstanding any provision of this Agreement to the contrary, in the event of a Change of Control, the treatment of the Option will
be governed by any applicable provisions of Section 21 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&#8239;&#8239;&#8239;&#8239;<U>Method
of Exercise</U>. Subject to the terms and conditions of this Agreement, the Option, to the extent vested and exercisable, may be exercised,
in whole or in part, by written notice to the Company or its designee, in substantially the form of&nbsp;attached hereto (or in such other
form acceptable to the Company, which may include electronic notice). Such notice shall state the number of Shares with respect to which
the Option is being exercised and shall be signed by the person exercising the Option (which signature may be provided electronically
in a form acceptable to the Company). Payment of the Exercise Price for such Shares shall be made in cash or its equivalent, or in such
other manner as may be approved by the Committee pursuant to the Plan. The Company shall deliver such Shares as soon as practicable after
the notice shall be received, provided, however, that (a) no fractional Shares shall be issued pursuant to this Option, and (b) the Company
may delay issuance of such Shares until completion of any action or obtaining of any consent, which the Company deems necessary under
any Applicable Laws (including, without limitation, state securities or &ldquo;blue sky&rdquo; laws). The Shares as to which the Option
shall have been so exercised shall be registered in the Company&rsquo;s share register in the name of the person so exercising the Option
and shall be delivered as provided above to or upon the written order of the person exercising the Option. In the event the Option shall
be exercised, by any person other than Participant, such notice shall be accompanied by appropriate proof of the right of such person
to exercise the Option. All Shares that shall be purchased upon the exercise of the Option as provided herein shall be fully paid and
nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&#8239;&#8239;&#8239;&#8239;<U>Restrictions</U>.
The Option shall not be transferable by Participant otherwise than by will or by the laws of descent and distribution, provided that the
Company may permit Participant to designate a beneficiary to exercise any vested portion of the Option in the event of Participant&rsquo;s
death. Except as provided above in this paragraph, the Option shall be exercisable, during Participant&rsquo;s lifetime, only by Participant
and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution,
attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of the Option or of any
rights granted hereunder contrary to the provisions of this Section&nbsp;3.3, or the levy of any attachment or similar process upon the
Option shall be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4 &#8239;&#8239;&#8239;&#8239;<U>Tax
Withholding</U>. Participant acknowledges and agrees that any income or other taxes due from Participant with respect to the Option (upon
exercise of the Option, the sale of Shares issued pursuant to the Option or otherwise) shall be Participant&rsquo;s responsibility. Without
limiting the foregoing, the parties agree that to the extent the Company or any Subsidiary is required to withhold any federal, state,
local, foreign or other taxes in connection with the exercise of the Option, then the Company or Subsidiary (as applicable) shall retain
a number of Shares otherwise deliverable hereunder with a value equal to the required withholding (based on the fair market value of the
Shares on the applicable date); provided that in no event shall the value of the Shares retained exceed the minimum amount of taxes required
to be withheld or such other amount that will not result in a negative accounting impact. Notwithstanding the foregoing, (a) to the extent
permitted by the Committee, Participant may elect, in accordance with procedures adopted by the Company from time to time, to&nbsp;pay
or provide for payment of the required tax withholding, and (b) in the event that the Company or any Subsidiary is required to withhold
taxes at any time other than upon exercise of the Option, the Company may withhold applicable taxes from other compensation payable to
Participant or require Participant to make arrangements satisfactory to the Company to provide for such tax withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5 &#8239;&#8239;&#8239;&#8239;<U>Rights
as Stockholder</U>. Participant shall have no rights as a stockholder with respect to Shares subject to this Agreement until exercise
of the Option and registration of the Shares in the Company&rsquo;s share register in the name of Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6&#8239;&#8239;&#8239;&#8239;<U>Compensation
Recovery Policy</U>. The Option and any Shares that may be delivered pursuant to this Agreement are subject to forfeiture or repayment
as may be provided pursuant to the Company&rsquo;s Compensation Recovery Policy (or any successor compensation recovery policy), as in
effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.&#8239;&#8239;&#8239;&#8239;Other
Provisions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1 &#8239;&#8239;&#8239;&#8239;<U>Administration</U>.
The Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation
and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules. All actions taken and all interpretations
and determinations made by the Committee in good faith shall be final, binding and conclusive upon Participant, the Company and all other
interested persons. No member of the Committee or the Board, or any employee or officer of the Company, shall be personally liable for
any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2 &#8239;&#8239;&#8239;&#8239;<U>Adjustments
Upon Specified Events</U>. The Committee may accelerate the vesting and exercisability of the Option in such circumstances as it, in its
sole discretion, may determine. In addition, upon the occurrence of certain events relating to the Company&rsquo;s common stock contemplated
by the Plan (including, without limitation, an extraordinary cash dividend on such Shares), the Committee shall make such adjustments
as the Committee deems appropriate to the Option in order to preserve the benefits intended to be made available to Participant under
this Agreement. Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided
in this Agreement and the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3 &#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of
the Company (or any other person or entity as designated by the Committee) at the Company&rsquo;s principal office, and any notice to
be given to Participant shall be addressed to Participant at Participant&rsquo;s last address reflected on the Company&rsquo;s records.
By a notice given pursuant to this Section 4.3, either party may hereafter designate a different address for notices to be given to that
party. A notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited
(with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4 &#8239;&#8239;&#8239;&#8239;<U>Titles
and Headings</U>. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5 &#8239;&#8239;&#8239;&#8239;<U>Governing
Law</U>. The laws of the State of Delaware, without reference to any conflict of law principles thereof, shall govern the interpretation,
validity, administration, enforcement and performance of the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6 &#8239;&#8239;&#8239;&#8239;<U>Conformity
to Laws</U>. Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions
of the Securities Act of 1933, as amended, the Exchange Act and the Code, and any and all regulations and rules promulgated thereunder,
state securities laws and regulations and all other applicable law. Notwithstanding anything herein to the contrary, the Plan shall be
administered, and the Option is granted and shall be administered only in such a manner as to conform to such laws, rules and regulations.
To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such
laws, rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7 &#8239;&#8239;&#8239;&#8239;<U>Amendments,
Suspension and Termination</U>. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified,
suspended or terminated at any time or from time to time by the Committee or the Board; <U>provided</U>, <U>however</U>, that except as
may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect
the Option in any material way without the prior written consent of Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8 &#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall
inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in Section
3.3 hereof, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9 &#8239;&#8239;&#8239;&#8239;<U>Not
a Contract of Employment</U>. Nothing in this Agreement or in the Plan shall confer upon Participant any right to continue to serve as
an employee or other service provider of the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10 &#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement</U>. The Plan, the Grant Notice and this Agreement (including all Exhibits thereto) constitute the entire agreement of the parties
and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11&#8239;&#8239;&#8239;&#8239;<U>Relation
to Other Benefits</U>. Any economic or other benefit to Participant under this Agreement or the Plan shall not be taken into account in
determining any benefits to which Participant may be entitled under any profit-sharing, retirement or other benefit or compensation plan
maintained by the Company or any of its Subsidiaries or affiliates, except as expressly provided in writing in such other plan&rsquo;s
governing instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12&#8239;&#8239;&#8239;&#8239;<U>Data
Privacy</U>. In order to administer the Plan, the Company may process personal data about Participant. Such data includes, but is not
limited to, the information provided in this Agreement and any changes thereto, other appropriate personal and financial data about Participant
such as home address and business addresses and other contact information, and any other information that might be deemed appropriate
by the Company to facilitate the administration of the Plan. Participant hereby gives explicit consent to the Company to process any such
personal data. Participant also gives explicit consent to the Company to transfer any such personal data outside the country in which
Participant works or is employed, including, if Participant is not a U.S. resident, to the United States, to transferees that shall include
the Company and other persons who are designated by the Company to administer the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13&#8239;&#8239;&#8239;&#8239;<U>Electronic
Delivery</U>. Participant hereby consents and agrees to electronic delivery of any documents that the Company may elect to deliver, including,
but not limited to, the Plan document, Plan Summary and Prospectus, grant or award notifications, account statements, annual and quarterly
reports, and all other forms of communications (&ldquo;<U>Prospectus Information</U>&rdquo;) in connection with this and any other Award
made or offered under the Plan. Participant has the right at any time to request that the Company deliver written copies of any and all
Prospectus Information at no charge. Participant also hereby consents to any and all procedures the Company has established or may establish
for an electronic signature system for delivery and acceptance of any such Prospectus Information that the Company may elect to deliver
and agrees that Participant&rsquo;s electronic response or signature is the same as, and shall have the same force and effect as, Participant&rsquo;s
manual signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><U>NOTICE OF EXERCISE
OF STOCK OPTION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt">To:</TD>
    <TD STYLE="font-size: 10pt"><B>Astrana Health, Inc.</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">I hereby exercise my
Stock Option to purchase _________ shares (the &ldquo;<U>Shares</U>&rdquo;) of the common stock, $0.001 par value, of Astrana Health,
Inc. (the &ldquo;<U>Company</U>&rdquo;), at the Exercise Price of $____&nbsp;per Share, pursuant to and subject to the terms of that Nonqualified
Stock Option Grant Notice dated ______________, 20__ and the Astrana Health, Inc. 2024 Equity Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">I understand the nature
of the investment I am making and the financial risks thereof. I am aware that it is my responsibility to have consulted with competent
tax and legal advisors about the relevant national, state and local income tax and securities laws affecting the exercise of the Option
and the purchase and subsequent sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">I am paying the Exercise
Price for the Shares as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 53%; padding-bottom: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt">Participant (signature)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt">Print Name</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 6pt">Date</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>tm2416687d1_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASTRANA HEALTH, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RESTRICTED STOCK GRANT NOTICE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Astrana Health, Inc. (the
 &ldquo;<U>Company</U>&rdquo;), pursuant to its 2024 Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;), hereby grants to the individual
listed below (&ldquo;<U>Participant</U>&rdquo;) the number of shares of the Company&rsquo;s common stock, par value $0.001, set forth
below (individually and collectively referred to as the &ldquo;<U>Restricted Shares</U>&rdquo;). The Restricted Shares are subject to
all of the terms and conditions set forth herein and in the Restricted Stock Agreement attached hereto as <U>Exhibit A</U> (the &ldquo;<U>Restricted
Stock Agreement</U>&rdquo;) and the Plan, each of which are incorporated herein by reference. Capitalized terms used but not defined in
this Grant Notice and the Restricted Stock Agreement shall have the meanings given to such terms in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify">Participant:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 60%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Grant Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Total Number of Restricted Shares:</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Vesting Schedule:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By signing below, Participant
agrees to be bound by the terms and conditions of the Plan, the Restricted Stock Agreement and this Grant Notice. Participant has reviewed
the Restricted Stock Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel
prior to executing this Grant Notice and fully understands all provisions of this Grant Notice, the Restricted Stock Agreement and the
Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Company and the Committee
(as defined in the Plan) upon any questions arising under the Plan, this Grant Notice or the Restricted Stock Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B><I>Important
Notice: This Agreement shall be void, AND THE RESTRICTED SHARES SHALL BE FORFEITED AUTOMATICALLY, if THE AGREEMENT has not been SIGNED
by Participant and returned to the Company within 30 days after the Grant Date. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">[signature
page follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the undersigned have executed this Grant Notice effective as of the Grant Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASTRANA HEALTH, INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO RESTRICTED STOCK GRANT NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RESTRICTED STOCK AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.&#8239;&#8239;&#8239;&#8239;General.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&#8239;&#8239;&#8239;&#8239;<U>Defined
Terms</U>. Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Grant Notice, unless
the context clearly indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2 &#8239;&#8239;&#8239;&#8239;<U>Incorporation
of Terms of Plan</U>. The Restricted Shares are subject to the terms and conditions of the Plan which are incorporated herein by reference.
In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.&#8239;&#8239;&#8239;&#8239;Grant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1 &#8239;&#8239;&#8239;&#8239;<U>Grant
of Restricted Shares</U>. In consideration of Participant&rsquo;s employment with the Company or a Subsidiary and for other good and valuable
consideration, effective as of the Grant Date set forth in the Grant Notice (the &ldquo;<U>Grant Date</U>&rdquo;), the Company grants
to Participant the Restricted Shares, upon the terms and conditions set forth in the Plan and this Agreement, subject to adjustments as
provided in Article VIII of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2 &#8239;&#8239;&#8239;&#8239;<U>Consideration
to the Company</U>. In consideration of the grant of the Restricted Shares by the Company, Participant agrees to render faithful and efficient
services to the Company or a Subsidiary. Nothing in the Plan or this Agreement shall confer upon Participant any right to continue in
the employ or service of the Company or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and its
Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason
whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary
and Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.&#8239;&#8239;&#8239;&#8239;Vesting,
Delivery, Restrictions, Etc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1 &#8239;&#8239;&#8239;&#8239;<U>Vesting</U>.
Subject to the terms and conditions of the Plan, the Restricted Shares shall vest at such times as are set forth in the Grant Notice;
provided, however, none of the Restricted Shares that have not become vested at the date of Participant&rsquo;s termination of employment
or service for any reason, with or without cause (including, but not limited to, death, Disability or Retirement), shall thereafter become
vested, except as may be otherwise provided by the Committee or as set forth in a written agreement between the Company and Participant.
Notwithstanding any provision of this Agreement to the contrary, in the event of a Change of Control, the treatment of the Restricted
Shares will be governed by any applicable provisions of Section 21 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&#8239;&#8239;&#8239;&#8239;<U>Restrictions</U>.
Unless and until the Restricted Shares vest as set forth in the Grant Notice, Participant shall have no right to sell, assign, transfer,
pledge or otherwise encumber the Restricted Shares in any manner. Any purported attempt to sell, assign, transfer, pledge or otherwise
encumber any Restricted Shares under this Agreement shall be void and shall result in the forfeiture and cancellation of such Restricted
Shares. Upon Participant&rsquo;s termination of employment or service for any reason, with or without cause (including, but not limited
to, death, Disability or Retirement), any Restricted Shares that are unvested as of the date of such termination of employment or service
(and whose vesting is not accelerated pursuant to this Agreement or the Plan) shall be forfeited, and Participant shall have no further
rights with respect to such Restricted Shares under this Agreement or otherwise. The Restricted Shares shall be registered in book entry
in the name of Participant and shall include a legend indicating the possibility of cancellation and the restrictions on transfer of the
Restricted Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3 &#8239;&#8239;&#8239;&#8239;<U>Tax
Withholding</U>. Subject to Section 3.4 below, the vesting of the Restricted Shares under this Agreement will result in Participant&rsquo;s
recognition of income for U.S. federal income tax purposes. The parties agree that to the extent the Company or any Subsidiary is required
to withhold any federal, state, local, foreign or other taxes in connection with the vesting or the grant of the Restricted Shares, then
such tax withholding shall be satisfied by the forfeiture of a number of Restricted Shares having a value equal to the required tax withholding
(based on the Fair Market Value per Share on the applicable date), provided that in no event shall the value of the Shares retained exceed
maximum statutory tax rates in the applicable taxing jurisdictions. Notwithstanding the foregoing, to the extent authorized by the Committee,
the Participant may be permitted to elect, in accordance with procedures adopted by the Company from time to time, to&nbsp;pay or provide
for payment of any required tax withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4 &#8239;&#8239;&#8239;&#8239;<U>Section
83(b) Election</U>. If Participant makes an election under Section 83(b) of the Code to be taxed with respect to the Restricted Shares
as of the date of transfer of the Restricted Shares rather than as of the date or dates upon which Participant would otherwise be taxable
under Section 83 of the Code, Participant shall be required to deliver a copy of such election to the Company promptly after filing such
election with the Internal Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5 &#8239;&#8239;&#8239;&#8239;<U>Rights
as Stockholder</U>. Upon issuance of the Restricted Shares and until the forfeiture or cancellation of the Restricted Shares, Participant
shall have, unless otherwise provided by the Committee, all the rights of a stockholder with respect to the Restricted Shares, subject
to the transferability and other restrictions set forth in this Agreement, including the right to receive all dividends and other distributions
paid or made with respect to the Restricted Shares; provided, however, that any extraordinary distributions with respect to the Company&rsquo;s
common stock received by Participant in the form of shares of such common stock shall be subject to the same vesting and other restrictions
as the Restricted Shares to which they relate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6&#8239;&#8239;&#8239;&#8239;<U>Compensation
Recovery Policy</U>. The Restricted Shares are subject to forfeiture or repayment as may be provided pursuant to the Company&rsquo;s Compensation
Recovery Policy (or any successor compensation recovery policy), as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.&#8239;&#8239;&#8239;&#8239;Other
Provisions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1 &#8239;&#8239;&#8239;&#8239;<U>Administration</U>.
The Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation
and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules. All actions taken and all interpretations
and determinations made by the Committee in good faith shall be final, binding and conclusive upon Participant, the Company and all other
interested persons. No member of the Committee or the Board, or any employee or officer of the Company, shall be personally liable for
any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the Restricted Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2 &#8239;&#8239;&#8239;&#8239;<U>Adjustments
Upon Specified Events</U>. The Committee may accelerate the vesting of the Restricted Shares in such circumstances as it, in its sole
discretion, may determine. In addition, upon the occurrence of certain events relating to the Company&rsquo;s common stock contemplated
by the Plan (including, without limitation, an extraordinary cash dividend on such Shares), the Committee shall make such adjustments
as the Committee deems appropriate to the Restricted Shares in order to preserve the benefits intended to be made available to Participant
under this Agreement. Participant acknowledges that the Restricted Shares are subject to adjustment, modification and termination in certain
events as provided in this Agreement and the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3 &#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of
the Company (or any other person or entity as designated by the Committee) at the Company&rsquo;s principal office, and any notice to
be given to Participant shall be addressed to Participant at Participant&rsquo;s last address reflected on the Company&rsquo;s records.
By a notice given pursuant to this Section 4.3, either party may hereafter designate a different address for notices to be given to that
party. A notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited
(with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4 &#8239;&#8239;&#8239;&#8239;<U>Titles
and Headings</U>. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5 &#8239;&#8239;&#8239;&#8239;<U>Governing
Law</U>. The laws of the State of Delaware, without reference to any conflict of law principles thereof, shall govern the interpretation,
validity, administration, enforcement and performance of the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6 &#8239;&#8239;&#8239;&#8239;<U>Conformity
to Laws</U>. Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions
of the Securities Act of 1933, as amended, the Exchange Act and the Code, and any and all regulations and rules promulgated thereunder,
state securities laws and regulations and all other applicable law. Notwithstanding anything herein to the contrary, the Plan shall be
administered, and the Restricted Shares are granted and shall be administered only in such a manner as to conform to such laws, rules
and regulations. To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary
to conform to such laws, rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7 &#8239;&#8239;&#8239;&#8239;<U>Amendments,
Suspension and Termination</U>. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified,
suspended or terminated at any time or from time to time by the Committee or the Board; <U>provided</U>, <U>however</U>, that except as
may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect
the Restricted Shares in any material way without the prior written consent of Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8 &#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall
inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in Section
3.2 hereof, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9 &#8239;&#8239;&#8239;&#8239;<U>Not
a Contract of Employment</U>. Nothing in this Agreement or in the Plan shall confer upon Participant any right to continue to serve as
an employee or other service provider of the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10 &#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement</U>. The Plan, the Grant Notice and this Agreement (including all Exhibits thereto) constitute the entire agreement of the parties
and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11&#8239;&#8239;&#8239;&#8239;<U>Relation
to Other Benefits</U>. Any economic or other benefit to Participant under this Agreement or the Plan shall not be taken into account in
determining any benefits to which Participant may be entitled under any profit-sharing, retirement or other benefit or compensation plan
maintained by the Company or any of its Subsidiaries or affiliates, except as expressly provided in writing in such other plan&rsquo;s
governing instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12&#8239;&#8239;&#8239;&#8239;<U>Data
Privacy</U>. In order to administer the Plan, the Company may process personal data about Participant. Such data includes, but is not
limited to, the information provided in this Agreement and any changes thereto, other appropriate personal and financial data about Participant
such as home address and business addresses and other contact information, and any other information that might be deemed appropriate
by the Company to facilitate the administration of the Plan. Participant hereby gives explicit consent to the Company to process any such
personal data. Participant also gives explicit consent to the Company to transfer any such personal data outside the country in which
Participant works or is employed, including, if Participant is not a U.S. resident, to the United States, to transferees that shall include
the Company and other persons who are designated by the Company to administer the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13&#8239;&#8239;&#8239;&#8239;<U>Electronic
Delivery</U>. Participant hereby consents and agrees to electronic delivery of any documents that the Company may elect to deliver, including,
but not limited to, the Plan document, Plan Summary and Prospectus, grant or award notifications, account statements, annual and quarterly
reports, and all other forms of communications (&ldquo;<U>Prospectus Information</U>&rdquo;) in connection with this and any other Award
made or offered under the Plan. Participant has the right at any time to request that the Company deliver written copies of any and all
Prospectus Information at no charge. Participant also hereby consents to any and all procedures the Company has established or may establish
for an electronic signature system for delivery and acceptance of any such Prospectus Information that the Company may elect to deliver
and agrees that Participant&rsquo;s electronic response or signature is the same as, and shall have the same force and effect as, Participant&rsquo;s
manual signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[END OF DOCUMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>tm2416687d1_ex10-5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASTRANA HEALTH, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RESTRICTED STOCK UNIT GRANT NOTICE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">Astrana Health, Inc., a
Delaware corporation (together with any successor thereof, the &ldquo;<U>Company</U>&rdquo;), pursuant to its 2024 Equity Incentive Plan,
as amended from time to time (the &ldquo;<U>Plan</U>&rdquo;), hereby grants to the holder listed below (&ldquo;<U>Participant</U>&rdquo;)
the number of restricted stock units set forth below (individually and collectively referred to as the &ldquo;<U>RSUs</U>&rdquo;). The
RSUs are subject to all of the terms and conditions set forth herein and in the Restricted Stock Unit Agreement attached hereto as <U>Exhibit
A</U> (the &ldquo;<U>RSU Agreement</U>&rdquo;) and the Plan, each of which is incorporated herein by reference. Capitalized terms not
specifically defined in this Grant Notice shall have the meanings specified in the Plan and/or RSU Agreement, unless the context clearly
indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-align: justify">Participant:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Grant Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Target Number of RSUs:</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Vesting Schedule:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B><I>Important
Notice: ThE RSU Agreement and this grant notice shall be void, AND THE RSU</I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif">S</FONT>
<FONT STYLE="text-transform: uppercase">SHALL BE FOrFEITED AUTOMATICALLY, if THis grant notice has not been SIGNED by Participant and
returned to the Company within 30 days after the Grant Date provided above. </FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">[SIGNATURE
PAGE FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By signing below, Participant
agrees to be bound by the terms and conditions of the Plan, the RSU Agreement and this Grant Notice. Participant has reviewed the RSU
Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing
this Grant Notice and fully understands all provisions of this Grant Notice, the RSU Agreement and the Plan. Participant hereby agrees
to accept as binding, conclusive and final all decisions or interpretations of the Company and the Committee (as defined in the Plan)
upon any questions arising under the Plan, this Grant Notice or the RSU Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF, </B>the
undersigned have executed this Grant Notice effective as of the Grant Date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASTRANA HEALTH, INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 3pt; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 3pt; padding-bottom: 3pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-top: 3pt; width: 5%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding-top: 3pt; border-bottom: Black 1pt solid; width: 42%; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; width: 5%; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-top: 3pt; width: 5%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;By:</FONT></TD>
    <TD STYLE="padding-top: 3pt; border-bottom: Black 1pt solid; width: 43%; padding-bottom: 3pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-top: 3pt; border-bottom: black 1pt solid; text-align: justify; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; text-align: justify; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 3pt; text-align: left; padding-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Name:</FONT></TD>
    <TD STYLE="padding-top: 3pt; border-bottom: Black 1pt solid; text-align: justify; padding-bottom: 3pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; padding-top: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-top: 3pt; border-bottom: black 1pt solid; text-align: justify; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; text-align: justify; padding-bottom: 3pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; text-align: justify; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: justify; padding-bottom: 3pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO RESTRICTED STOCK UNIT GRANT NOTICE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RESTRICTED STOCK UNIT AGREEMENT </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">Pursuant to the Restricted
Stock Unit Grant Notice (the &ldquo;<U>Grant Notice</U>&rdquo;) to which this Restricted Stock Unit Agreement (this &ldquo;<U>Agreement</U>&rdquo;)
is attached, Astrana Health, Inc., a Delaware corporation (together with any successor thereof, the &ldquo;<U>Company</U>&rdquo;), has
granted certain restricted stock units (the &ldquo;<U>RSUs</U>&rdquo;) to Participant under the Company&rsquo;s 2024 Equity Incentive
Plan, as amended from time to time (the &ldquo;<U>Plan</U>&rdquo;) as indicated in the Grant Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>1.
<U>General</U>.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">1.1 <U>Defined Terms</U>.
Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and/or the Grant Notice, unless the context
clearly indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">1.2 <U>Incorporation of
Terms of Plan</U>. The RSUs are subject to the terms and conditions of the Plan, which are incorporated herein by reference. In the event
of any inconsistency between the Plan and this Agreement or the Grant Notice, the terms of the Plan shall control.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>2.
<U>Grant</U>.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">2.1 <U>Grant of RSUs</U>.
In consideration of Participant&rsquo;s employment with or service to the Company or a Subsidiary and for other good and valuable consideration,
effective as of the Grant Date set forth in the Grant Notice (the &ldquo;<U>Grant Date</U>&rdquo;), the Company grants to Participant
the RSUs, upon the terms and conditions set forth in the Plan, the Grant Notice and this Agreement, subject to adjustments as provided
in Article 16 of the Plan. Each RSU represents the contingent right to receive one Share and shall at all times be equal to the value
of one Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">2.2 <U>Consideration to
the Company</U>. In consideration of the grant of the RSUs by the Company, Participant agrees to render faithful and efficient services
to the Company or a Subsidiary. Nothing in the Plan or this Agreement shall confer upon Participant any right to continue in the employ
or service of the Company or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and its Subsidiaries,
which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever,
with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and
Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>3.
<U>Vesting, Restrictions, Settlement and Etc.</U></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">3.1 <U>Vesting</U>. Subject
to the terms and conditions of the Plan, the RSUs shall vest at such times and subject to such conditions as are set forth in the Grant
Notice; <U>provided</U>, <U>however</U>, that no RSUs that are unvested as of the date of Participant&rsquo;s termination of employment
or service for any reason, with or without cause (including, but not limited to, death, disability or retirement), shall thereafter become
vested, except as may be otherwise provided by the Committee or as set forth in a written agreement between the Company and Participant.
Notwithstanding any provision of this Agreement to the contrary, in the event of a Change of Control, the treatment of the RSUs will be
governed by any applicable provisions of Section 21 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">3.2 <U>Restrictions</U>.
Participant shall have no right to sell, assign, transfer, pledge or otherwise encumber RSUs in any manner. Any purported attempt to sell,
assign, transfer, pledge or otherwise encumber any RSUs under this Agreement shall be void and shall result in the forfeiture and cancellation
of such RSUs. Upon Participant&rsquo;s termination of employment or service for any reason, with or without cause (including, but not
limited to, death, disability or retirement), any RSUs that are unvested as of the date of such termination of employment or service (and
whose vesting is not accelerated pursuant to this Agreement or the Plan) shall be forfeited, and Participant shall have no further rights
with respect to such RSUs under this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">3.3 <U>Settlement</U>. The
RSUs shall be registered in book entry in the name of Participant until they have vested in accordance with this Agreement. Upon vesting
of any of the RSUs, the Company shall deliver the corresponding number of Shares to Participant within 30 days following the date on which
such RSUs vested. Upon such delivery to Participant, such Shares will not be subject to any restrictions other than those that may arise
under the securities laws or the Company&rsquo;s policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">3.4 <U>Tax Withholding</U>.
To the extent the Company or any Subsidiary is required to withhold any federal, state, local, foreign or other taxes in connection with
the delivery of Shares under this Agreement, then the Company or Subsidiary (as applicable) shall retain a number of Shares otherwise
deliverable hereunder with a value equal to the required withholding (based on the Fair Market Value per Share on the applicable date);
<U>provided</U>, <U>however</U>, that in no event shall the value of the Shares retained exceed maximum statutory tax rates in the applicable
taxing jurisdictions. Notwithstanding the foregoing, to the extent authorized by the Committee, the Participant may be permitted to elect,
in accordance with procedures adopted by the Company from time to time, to&nbsp;pay or provide for payment of any required tax withholding.
To the extent that the Company or any Subsidiary is required to withhold any federal, state, local, foreign or other taxes at any time
other than upon delivery of Shares under this Agreement, the Company, in its discretion may (a) require Participant to&nbsp;pay or provide
for payment of the required tax withholding, or (b)&nbsp;satisfy the required tax withholding by deduction from any amount of compensation
otherwise payable in cash to Grantee (including any cash dividend equivalent payments pursuant to Section 3.6 of this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">3.5 <U>No Stockholder Rights</U>.
Participant shall not possess any incidents of ownership (including, without limitation, dividend and voting rights) in the Shares underlying
the RSUs unless and until such Shares have been delivered to Participant in accordance with Section 3.3. The obligations of the Company
pursuant to this Agreement are merely that of an unfunded and unsecured promise of the Company to deliver Shares (and cash dividend equivalents,
if any, pursuant to Section 3.6 hereof) in the future and subject to the terms and conditions of this Agreement, and the rights of Participant
hereunder are no greater than those of an unsecured general creditor. No Company assets shall be held or set aside as security for the
Company&rsquo;s obligations pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">3.6 <U>Dividend Equivalents</U>.
From and after the Grant Date and until the earlier of (a) the time when the Shares underlying the vested RSUs (if any) are delivered
to Participant in accordance with this Agreement, or (b) the time that the RSUs are forfeited in accordance with this Agreement, on each
date, if any, that the Company pays a cash dividend to holders of its Shares generally, the Company will credit Participant&rsquo;s account
hereunder with the right to receive a cash amount equal to the product of (x) the dollar amount of the cash dividend paid per Share to
stockholders on such date multiplied by (y) the total number of unpaid RSUs credited to Participant&rsquo;s account under this Agreement
as of such date. Subject to and conditioned upon the vesting of the underlying RSUs, the aggregate amount of any such dividend equivalents
credited to Participant&rsquo;s account hereunder shall be paid to Participant in cash (without interest), at the same time and in the
same proportion that the Shares underlying any vested RSUs are delivered to Participant, and the Participant&rsquo;s right to receive
any such dividend equivalents shall be automatically and correspondingly forfeited to the extent that the RSUs are forfeited pursuant
to the terms of this Agreement and the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">3.7 <U>Compensation Recovery
Policy</U>. The RSUs and any Shares that may be delivered pursuant to this Agreement are subject to forfeiture or repayment as may be
provided pursuant to the Company&rsquo;s Compensation Recovery Policy (or any successor compensation recovery policy), as in effect from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>4.
<U>Other Provisions</U>.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.1 <U>Administration</U>.
The Committee shall have the power to interpret the Plan, the Grant Notice and this Agreement, and to establish, amend or waive such rules
for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such
rules. All actions taken and all interpretations and determinations made by the Committee in good faith shall be final, binding and conclusive
upon Participant, the Company and all other interested parties, including, but not limited to, Subsidiaries, stockholders, Directors,
Consultants, Employees, other Plan participants, and any of their estates and beneficiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.2 <U>Adjustments Upon Specified
Events</U>. The Committee may accelerate the vesting of all or a portion the RSUs in such circumstances as it, in its sole discretion,
may determine. Participant acknowledges that the RSUs are subject to adjustment, modification and termination in certain events as provided
in this Agreement and the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.3 <U>Notices</U>. Any notice
to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of the Company
(or any other person or entity as designated by the Committee) at the Company&rsquo;s principal office, and any notice to be given to
Participant shall be addressed to Participant at Participant&rsquo;s last address reflected on the Company&rsquo;s records. By a notice
given pursuant to this Section&nbsp;4.3, either party may hereafter designate a different address for notices to be given to that party.
A notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with
postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.4 <U>Titles and Headings</U>.
Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.5 <U>Governing Law</U>.
The laws of the State of Delaware, without reference to any conflict of law principles thereof, shall govern the interpretation, validity,
administration, enforcement and performance of the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.6 <U>Conformity to Laws</U>.
Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all provisions
of the Securities Act of 1933, as amended, the Exchange Act and the Code, and any and all regulations and rules promulgated thereunder,
state securities laws and regulations and all other applicable law. Notwithstanding anything herein to the contrary, the Plan shall be
administered, and the RSUs are granted and shall be administered, only in such a manner as to conform to such laws, rules and regulations.
To the extent permitted by applicable law, the Plan, the Grant Notice and this Agreement shall be deemed amended to the extent necessary
to conform to such laws, rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.7 <U>Section 409A of the
Code</U>. The Award of RSUs evidenced by this Agreement is intended to be exempt from, or to comply with, the requirements of Section&nbsp;409A
of the Code, and this Agreement shall be interpreted and administered in accordance with such intent. Accordingly, solely to the extent
necessary to comply with the requirements of Section 409A of the Code: (a) the termination of Participant&rsquo;s employment or other
service shall be interpreted to mean the Participant&rsquo;s &ldquo;separation from service&rdquo; within the meaning of Section 409A
of the Code; (b) if Participant is a &ldquo;specified employee&rdquo; (as determined by the Company in accordance with Section 409A of
the Code), settlement of any vested RSUs (and payment of any related dividend equivalents) as a result of Participant&rsquo;s separation
from service shall be delayed until the first business day that is at least six months after the date of Participant&rsquo;s separation
from service or, if earlier, the date of Participant&rsquo;s death; and (c) a Change of Control shall be interpreted to mean an event
that qualifies as both a &ldquo;Change of Control&rdquo; as defined in the Plan and a &ldquo;change in control event&rdquo; within the
meaning of Section 409A of the Code and Treasury Regulation &sect;1.409A-3(i)(5). Notwithstanding the foregoing, the tax treatment of
the RSUs is not warranted or guaranteed. Neither the Company and its Subsidiaries, nor their respective affiliates, directors, officers,
employees and advisers shall be held liable for any taxes, interest, penalties or other monetary amounts that may owed by the Participant
or other taxpayer as a result of the Award of RSUs or this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.8 <U>Amendments, Suspension
and Termination</U>. To the extent permitted by the Plan, the Grant Notice and this Agreement may be wholly or partially amended or otherwise
modified, suspended or terminated at any time or from time to time by the Committee or the Board; <U>provided</U>, <U>however</U>, that
except as may otherwise be provided by the Plan or Section 4.6 of this Agreement, no amendment, modification, suspension or termination
of this Agreement shall adversely affect the RSUs in any material way without the prior written consent of Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.9 <U>Successors and Assigns</U>.
The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit
of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in Section&nbsp;3.2 hereof, this Agreement
shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.10 <U>Not a Contract of
Employment</U>. Nothing in this Agreement, the Grant Notice or in the Plan shall confer upon Participant any right to continue to serve
as an employee or other service provider of the Company or any of its Subsidiaries or affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.11 <U>Relation to Other
Benefits</U>. Any economic or other benefit to Participant under this Agreement or the Plan shall not be taken into account in determining
any benefits to which Participant may be entitled under any profit-sharing, retirement or other benefit or compensation plan maintained
by the Company or any of its Subsidiaries or affiliates, except as expressly provided in writing in such other plan&rsquo;s governing
instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.12 <U>Data Privacy</U>.
In order to administer the Plan, the Company may process personal data about Participant. Such data includes, but is not limited to, the
information provided in this Agreement and any changes thereto, other appropriate personal and financial data about Participant such as
home address and business addresses and other contact information, and any other information that might be deemed appropriate by the Company
to facilitate the administration of the Plan. Participant hereby gives explicit consent to the Company to process any such personal data.
Participant also gives explicit consent to the Company to transfer any such personal data outside the country in which Participant works
or is employed, including, if Participant is not a U.S. resident, to the United States, to transferees that shall include the Company
and other persons who are designated by the Company to administer the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.13 <U>Electronic Delivery</U>.
Participant hereby consents and agrees to electronic delivery of any documents that the Company may elect to deliver, including, but
not limited to, the Plan document, Plan Summary and Prospectus, grant or award notifications, account statements, annual and quarterly
reports, and all other forms of communications (&ldquo;<U>Prospectus Information</U>&rdquo;) in connection with this and any other Award
made or offered under the Plan. Participant has the right at any time to request that the Company deliver written copies of any and all
Prospectus Information at no charge. Participant also hereby consents to any and all procedures the Company has established or may establish
for an electronic signature system for delivery and acceptance of any such Prospectus Information that the Company may elect to deliver
and agrees that Participant&rsquo;s electronic response or signature is the same as, and shall have the same force and effect as, Participant&rsquo;s
manual signature.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">4.14 <U>Entire Agreement</U>.
The Plan, the Grant Notice and this Agreement (including any Exhibits to any of the foregoing) constitute the entire agreement of the
parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject
matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[END OF DOCUMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ameh-20240612.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaSOqbOdzZR+OYkxtmB2ben6fycgw/4FfS95Ul1m0X8G -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:AMEH="http://apollomed.net/20240612" elementFormDefault="qualified" targetNamespace="http://apollomed.net/20240612">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://apollomed.net/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ameh-20240612_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ameh-20240612_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ameh-20240612_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ameh-20240612_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://apollomed.net/role/Cover" xlink:href="ameh-20240612.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://apollomed.net/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140143873087200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 12,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ASTRANA HEALTH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001083446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4472349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1668 S. Garfield Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alhambra<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">282-0288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ASTH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #L@<Q8!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .R!
MS%CD0.:![@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( .R!S%B97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ [(',6$(9RNY4
M!   "1$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( .R!S%B?H!OPL0(  .(,   -              "
M 9<,  !X;"]S='EL97,N>&UL4$L! A0#%     @ [(',6)>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  .L3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2416687d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apollomed.net/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ameh-20240612.xsd</File>
    <File>ameh-20240612_lab.xml</File>
    <File>ameh-20240612_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2416687d1_8k.htm">tm2416687d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2416687d1_8k.htm": {
   "nsprefix": "AMEH",
   "nsuri": "http://apollomed.net/20240612",
   "dts": {
    "schema": {
     "local": [
      "ameh-20240612.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ameh-20240612_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ameh-20240612_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2416687d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://apollomed.net/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2416687d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2416687d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-24-070847-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-070847-xbrl.zip
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M04T>DN)Y\!Y*0+U;6'IL-YD!Q &AT^T0($@&H6:43Y#F+.+BF=<>=YCQK1P
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M;440*("V3 X.0J25CB&X$T1!2&1'Y"\!JL1"XO;AP3K;=XE=0=%O6,,!*X.
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M^?M+;?^"-PV"Y:"AP5S$"3".=!6D?R[THLG5ZH%.J'+3%![ITES9AI["%T6
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MUTG5 3S#:^]>3EU<VC(9/#)-X$<;\],;H/?X>4!UW?_\:#)"L#= LVW;-.G
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MUC_]9!_U9\T+HU=-FA+6*DEV&J8+AI@>$]([HXY.?TA[):>4WS*7G)S4%U2
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MS@;=%@X1,($X: WL2(Q=>!XQF!^^**!MX%8%?$W]&.)&:B, CA"T!Q2'20T
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M  #*VP$ %@   '1M,C0Q-C8X-V0Q7V5X,3 M,2YH=&WM?>MSVT:VYW=6\7_
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MTLK_$W9XX1G8XLT+T[9 A78D'.& -MX]\7_=NY=\7Y@R_P:.P+EY"L/^>V-
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M@4Z."O934V%<GA@$<4[,/8NU9"?D]UX5&26K(9M2/.?8=U>1'<W#!BO8?I7
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M^YBSP=4DL"I=_=Q7BVUI!/5=&@\''1S17T_UKX'J1P)K@Q032;/J@5^FT3
M 1AER0BT)C9:)0UR=C*_.<A!]#4R27Q*EY0F0]Q?%<Z@#!5XN ]K'-\0UDC"
MJ,9TTGL?\K,]FP?^[.MF-J@>7N(EL\>!DWO?X9,_02K*E_M)11F")_R^M)3(
M>#>DJ% _7IVCLH.W_"Y%Y3\]124"VO&ITE6$>:8!B_("<_CDCTE=&;L[FL9R
M TK)3G&D3Y#2PHDR'Y73,G+*/T$6"9;A#=)(AHMS0.;S+F&:K^_"-/L-TWQ]
M%Z;Y7,_??UQ*UW6R<\?TKALDT^VE>DTGU^1Z11?A.GRSWYOV-9W<G/>5W*5]
M_5G3OG[SP?B8%##*^/K-:8S#%+#(I'=+!YM.#H[D]I\/YL/J4<L9*?/D=VK\
M.G-LEWH-A4#]1^6-@;C8/7$L^0/SQA@<9\?$L>0N;^P_.6]E](!]\AR6Z21R
M5FV;P#\JGV7XR.GDYN26Y#9R6Z:3'9-;DDAN2UR=[.6Y'"4_Z_2'-"K"IQ/-
M-=&YW"%_##SOC+XK\1:7PX&'GQ7)A6#*6@_[+AJ=6U.""$4O$.B%S^;7JJ9I
MLMJ47;$N96&9I7RZ]?,K!\0Z?J40K<+WO;I UZ=%^;59.6$^2&<;5Z!7-4(>
MWI>J9 ;,(SQ.A\$AO<?^J]OVV+\5 #^7\T3-FC[>4S\89Q"I;] A=.>I/W!/
M?9]. N3OW^ZG]QS1/V ZT3CDC7\P,-BBSF?MO =0B9<-Z/BFBE*-@&F9_6 0
M5#%AQN3(W%-%J1H] #$]# Z[/Z?<*8.F/E=["YOQ5E'-.&YAL4+,H &QI &E
M<.IDGPQ1^1H>!:2K@B4Z@K<D67[)*N2-4+:9-EQ\!H]6F]:(C>0[=/ND8A,>
M?)E,"!Z;L)4D!PAN*,REL4F6%CYGU.!2=E:X$$UBLV7#S"T01ADB_@=7K\ML
MX><@*]93:.GT.Z!:25,8"K^/+9%",?B[3-V?.>ECW'@9L5<8!\OUF"*K1>7[
MID,>QT1)RQ1Y;Z);YG.T5*S?K@O?FEIA0#I4+O_,1I$)\VF'B-*WQGUZI6;C
MD94^(!:W2]SO^/Y=X&^_@;_C^W>1O\_U!.XEA/$<YE/GY,C!+BE<OF"L9A$4
M=PAHFZI#&$' LQ*/H16I\PKEO*KQL0$1HME5#'\W% <>$ R'<G!@($!:D%;(
MQ[$;9NF=TY1B:J&R;M1S0O5=U2X)^A6C5I'8*-@$)8YR0/)@+]$-2=$[:=L:
M/4DV=6=('I)*K7YX0R*?Z?:%3[0>&&^]K1]JNM\X?UW<,X$6$SJU0#O$?K]9
MU2Y-0WT_UZ7)S_$/K)0ZKYANO%X%:VXJ 9E.+K9K_&6A6IAR]JWN<KJC)I8.
M%&IO%+.;DIPGJAII:SO?-[S@66_!&>I^\/ZZH]A.C\0GV00MUJU8[<H12K0X
M$VQM+  <.")[ZK&S0V3GHX9Y$.A/DV$4-)Q/_Y&;2H)@8]HIMJO.%HO-:F/!
MPBU31-A2N1FY7<Z\!TN!!D/-LNN[B<0]3V' C'Q?/?VW1Q3S =I"FZU&[ GQ
M&=1 #=0<A8=2]8,(.PHV62\@I?T"%C@T;F?--;?FT=&+S+V?\%9>N\-@K]YG
M^_6^?;9@_!7=IW+<\F!WWML[[^TNWELDED_JPB7?Y 9)\'>Y;9F*?Y_O5H25
M' COP$U=QAM1MA0EP[1[9<$C)VM8UIONXA*FVN4_SB?\$7D7TAGQ&F_400B
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M"&$(Q.(3%EN&?_)9RST?CP5R,9&TQGYQ_'C#40O'7/'AP+(2F$>2N=]MLD
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M&6S+X1*#GTP84]3 [TID!=-"E.;% A(X'E=5UKCY2*#?J%M)11,Z-#Q.YC$
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MHS1[)8ZQ#/0.$5;7\KC?;)YJ72P-SNJ\.#P]^@/WXL7[T:_';_X?4$L#!!0
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M80"S1)+1M?93U;V%@7-+@<L14>]VS#;E8/(U[D^)YCU()["S@*'AH"4W.-U
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M<OXMUYT8%=VLZ$I&:=+9[5Q%Z'W;[#^M!=%P@@FDZ6%";(;N%HMDC"LDPYP
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M +$5XCV$M+Z5Y6CM5FTX;S\0 'P3M[XC%$R#"UA,-?P#5Z?C($GG22IS,SU
M.S*H5$!,77$JYSH'DOXG(I86761($44NXB07H1KK6.$JVZU\JC/Q!FE)7"1
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M9A>U2F0+#?00B_T=$<HE$,TX-\126G1=T$P#$Q1!S#P\\>WB0UMN_-]1GDM
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M/V'P3_>Z#1/]^+>[W7X;Q-O;[KF7VSWVB;-^[N#/9R.7"SE3_PK!; Y4?*$
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M<*9C%(C2V7OMUM#+,]4*%^<@7NE@!W?ZP5WE+7PI8?N>)6%:@*HC+Y>\%0^
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MK)?Z'NW\"M'.@WN-=MY3Z-%28>-W]EZ<7)[]@93_XNWPU_-7_P]02P,$%
M  @ [(',6'HXCU-$'0  4Y8  !8   !T;3(T,38V.#=D,5]E>#$P+34N:'1M
M[5WK4QM'MO^N*OT/?5VU*:B2L0VVL\&.JP3(-K4$N" G-[6U'UJ:%IIX-"//
M Z']Z^]Y=4_/0R <L)W@_; .DJ;[].GS/K_N>?U^^,O1FV[G]?M!_P#^5?B_
MU\/#X='@S>LG_"]\^T2^?KUW<O"[.A_^?C3X^=$DB?-=]>SI/%?#<&8R=6P6
MZBR9Z;C''_34N4G#R2-X$!X]O>USK]1,IQ=AO*OPIT]?J=Q<Y8]U%%[ 1VEX
M,<T?O7F]]V9P-0U'80X#;KUX_60/R#Z]QPE_B$?9_-4]S3$V<6Y26E7_?'C6
M/^XK8/S1\'U/'1[O;]WCZKR9MY]N/U>#__UP./P=9QT<#P]_':C3H_[Q%YC_
M2['W]8<W9P-@\>'^<'  DYSL_TM].#X<JG? ]:$Z/AD>[@]>/_GPYA[7_$>1
MY>%D*1^&<6!PT.?_W/KIQ?R^)>V&N?M9GNI8J_=&1_D4I"\>;_64[G8.3*07
M.C5JG*3S)-5YF,1J(T\N3#XUJ5J$^53I>*FR8CPV69:D"C\WR:2'_Z%^B()/
M1?(*N+^?S.;P0V3Q#RE]N-E3\R+-"AWG*D]4F&>*1?%3$>9+) %H#"^-.HU@
MJ=V.SI2>&: \4),TF:D<UHX/TK\;U=GPD>I42-5HJ2Y@F3 1/@8/3),H@%5$
M89;#J",3)0NUX8VBTSP<AT!W[@_6[>"S<3$;P;/)1*4&N!>.<8@L3\8?51'C
M8C*3JTF2 H-D8.!Z>!D&A8ZB)3 M )Y&D1GC&N&#U$Q,FL(80!LLM;J>L_,/
MF4_"EAI.3;>#'RO<G:P8_0$CT;-1A$3A\R#\LTQF@KEQ[WRRD"5A3-_#/_C
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M7Z@OLX+M3_9.#G['0W)/W@]_.7KS_U!+ 0(4 Q0    ( .R!S%C6,$M]+0,
M .8+   1              "  0    !A;65H+3(P,C0P-C$R+GAS9%!+ 0(4
M Q0    ( .R!S%B6(Z]-_0H  ("&   5              "  5P#  !A;65H
M+3(P,C0P-C$R7VQA8BYX;6Q02P$"% ,4    " #L@<Q8R6.C@UD'  #75P
M%0              @ &,#@  86UE:"TR,#(T,#8Q,E]P<F4N>&UL4$L! A0#
M%     @ [(',6.I4G<!@'@  VMX  !(              ( !&!8  '1M,C0Q
M-C8X-V0Q7SAK+FAT;5!+ 0(4 Q0    ( .R!S%BL5/M5W4L  ,K; 0 6
M          "  :@T  !T;3(T,38V.#=D,5]E>#$P+3$N:'1M4$L! A0#%
M  @ [(',6+B#&6$P'P  H:P  !8              ( !N8   '1M,C0Q-C8X
M-V0Q7V5X,3 M,BYH=&U02P$"% ,4    " #L@<Q8]BX)S'4>  !_J@  %@
M            @ $=H   =&TR-#$V-C@W9#%?97@Q,"TS+FAT;5!+ 0(4 Q0
M   ( .R!S%CHP&VU-1D  "&'   6              "  <:^  !T;3(T,38V
M.#=D,5]E>#$P+30N:'1M4$L! A0#%     @ [(',6'HXCU-$'0  4Y8  !8
M             ( !+]@  '1M,C0Q-C8X-V0Q7V5X,3 M-2YH=&U02P4&
/  D "0!9 @  I_4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>tm2416687d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ameh-20240612.xsd" xlink:type="simple"/>
    <context id="AsOf2024-06-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2024-06-12</startDate>
            <endDate>2024-06-12</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-06-12" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-06-12" id="Fact000004">0001083446</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-06-12" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-06-12" id="Fact000010">2024-06-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-06-12" id="Fact000011">ASTRANA HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-06-12" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-06-12" id="Fact000013">001-37392</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-06-12" id="Fact000014">95-4472349</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-06-12" id="Fact000015">1668 S. Garfield Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-06-12" id="Fact000016">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-06-12" id="Fact000017">Alhambra</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-06-12" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-06-12" id="Fact000019">91801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-06-12" id="Fact000020">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-06-12" id="Fact000021">282-0288</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-06-12" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-06-12" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-06-12" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-06-12" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-06-12" id="Fact000026">Common     Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-06-12" id="Fact000027">ASTH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-06-12" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-06-12" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
